U.S. patent application number 13/067111 was filed with the patent office on 2011-11-10 for preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound.
This patent application is currently assigned to BTG International Ltd.. Invention is credited to Isao Kaneko, Kazuo Koyama, Shinji Marumoto, Masaki Meguro, Yasuhiro Nakagami, Tomiichiro Oda.
Application Number | 20110275641 13/067111 |
Document ID | / |
Family ID | 26624724 |
Filed Date | 2011-11-10 |
United States Patent
Application |
20110275641 |
Kind Code |
A1 |
Meguro; Masaki ; et
al. |
November 10, 2011 |
Preventives or remedies for Alzheimer's disease, or amyloid protein
fibril-formation inhibitors, which include a nitrogen-containing
heteroaryl compound
Abstract
The present invention relates to preventives or remedies for
Alzheimer's disease, or to amyloid protein fibril-formation
inhibitors, which include as an active ingredient a compound of
general formula (I) below or a pharmacologically permitted salt
thereof; and also to nitrogen-containing heteroaryl derivatives
having specific substituents, or pharmacologically permitted salts
thereof, which are valuable as preventives or remedies for
Alzheimer's disease, or as amyloid protein fibril-formation
inhibitors: ##STR00001## (where, R.sup.1 and R.sup.2 are H or
alkyl; Z.sup.1 and Z.sup.2 are H, alkyl, alkoxy, haloalkyl or
halogeno; Z.sup.3 is alkoxy, SH, alkylthio, NH.sub.2, mono- or
di-alkylamino, OH or halogeno; Z.sup.4 and Z.sup.5 are H or
halogeno; and A is 4,6-pyrimidine-1,3-diyl,
1,3,5-triazine-2,6-diyl, etc).
Inventors: |
Meguro; Masaki; (Tokyo,
JP) ; Oda; Tomiichiro; (Tokyo, JP) ; Nakagami;
Yasuhiro; (Tokyo, JP) ; Marumoto; Shinji;
(Tokyo, JP) ; Koyama; Kazuo; (Tokyo, JP) ;
Kaneko; Isao; (Tokyo, JP) |
Assignee: |
BTG International Ltd.
London
GB
|
Family ID: |
26624724 |
Appl. No.: |
13/067111 |
Filed: |
May 10, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12068407 |
Feb 6, 2008 |
8003645 |
|
|
13067111 |
|
|
|
|
10497183 |
Oct 19, 2004 |
7589105 |
|
|
PCT/JP02/12265 |
Nov 25, 2002 |
|
|
|
12068407 |
|
|
|
|
Current U.S.
Class: |
514/245 ;
514/247; 514/256; 514/274; 514/275 |
Current CPC
Class: |
C07D 251/70 20130101;
A61K 31/53 20130101; A61P 7/00 20180101; A61P 3/10 20180101; A61P
9/00 20180101; C07D 239/48 20130101; A61P 25/02 20180101; C07D
237/20 20130101; A61K 31/50 20130101; A61P 13/12 20180101; C07D
241/20 20130101; C07D 251/52 20130101; A61P 25/00 20180101; A61P
35/00 20180101; C07D 237/22 20130101; A61P 43/00 20180101; A61K
31/505 20130101; A61P 25/28 20180101; C07D 251/18 20130101; C07D
251/48 20130101; C07D 239/50 20130101 |
Class at
Publication: |
514/245 ;
514/256; 514/275; 514/247; 514/274 |
International
Class: |
A61K 31/53 20060101
A61K031/53; A61K 31/50 20060101 A61K031/50; A61P 25/28 20060101
A61P025/28; A61P 25/02 20060101 A61P025/02; A61P 7/00 20060101
A61P007/00; A61P 25/00 20060101 A61P025/00; A61P 35/00 20060101
A61P035/00; A61P 9/00 20060101 A61P009/00; A61K 31/505 20060101
A61K031/505; A61P 3/10 20060101 A61P003/10 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 28, 2001 |
JP |
2001-361847 |
Jul 2, 2002 |
JP |
2002-192777 |
Claims
1-18. (canceled)
19. A method of treating a patient in need of therapy for an
amyloidosis comprising administering to the patient a
therapeutically effective amount of a nitrogen-containing
heteroaryl compound of the formula (I): ##STR00015## wherein
R.sup.1 and R.sup.2 each independently represent a hydrogen atom or
a C.sub.1-6 alkyl group, Z.sup.1 and Z.sup.2 each independently
represent a hydrogen atom, C.sub.1-6 alkyl-group, C.sub.1-6 alkoxy
group, halo-C.sub.1-6 alkyl group or halogen atom, Z.sup.3
represents a C.sub.1-6 alkoxy group, mercapto group, C.sub.1-6
alkylthio group, amino group, mono- or di-C.sub.1-6 alkylamino
group, hydroxy group or halogen atom, Z.sup.4 and Z.sup.5 each
independently represent a hydrogen atom or halogen atom, and
wherein A represents a group of formula (V) below ##STR00016##
wherein R.sup.9 represents a C.sub.1-6 alkyl group, C.sub.1-6
alkoxy group, mercapto group, C.sub.1-6 alkylthio group, amino
group, mono- or di-C.sub.1-6 alkylamino group or hydroxy group, or
pharmacologically permitted salt thereof.
20. A method according to claim 19 wherein the nitrogen-containing
heteroaryl compound is of the formula (VII) ##STR00017## where
R.sup.1 and R.sup.2 each independently represent a hydrogen atom or
C.sub.1-6 alkyl group, Z.sup.1 and Z.sup.2 each independently
represent a hydrogen atom, C.sub.1-6 alkyl group, C.sub.1-6 alkoxy
group, halogen atom or halo-C.sub.1-6 alkyl group, Z.sup.4 and
Z.sup.5 each independently represent a hydrogen atom or halogen
atom, and A represents a group of formula (V): ##STR00018## where
R.sup.9 represents a C.sub.1-6 alkyl group, C.sub.1-6 alkoxy group,
mercapto group, C.sub.1-6 alkylthio group, amino group, mono- or
di-C.sub.1-6 alkylamino group or hydroxy group or pharmacologically
permitted salt thereof.
21. A method according to claim 19, wherein R.sup.1 and R.sup.2 are
each independently a hydrogen atom or C.sub.1-2 alkyl group.
22. A method according to claim 19, wherein R.sup.1 and R.sup.2 are
hydrogen atoms.
23. A method according to claim 19, wherein A is a group of formula
(V) where R.sup.9 is a C.sub.1-5 alkyl, C.sub.1-4 alkoxy or a
C.sub.1-4 alkylthio group.
24. A method according to claim 19, wherein A is a group of formula
(V) where R.sup.9 is a C.sub.2-4 alkyl or a butoxy group.
25. A method according to claim 19, wherein A is a group of formula
(V) where R.sup.9 is a C.sub.2-4 alkyl group.
26. A method according to claim 19, wherein Z.sup.1 and Z.sup.2 are
each independently a hydrogen atom or para-position fluorine atom,
chlorine atom or C.sub.1-2 alkyl group, the hydroxy group on the
phenyl ring to which Z.sup.1 is bonded is in the meta-position, and
Z.sup.4 and Z.sup.5 are hydrogen atoms.
27. A method according to claim 19, wherein Z.sup.1 and Z.sup.2 are
hydrogen atoms or para-position methyl groups, the hydroxy group on
the phenyl ring to which Z.sup.1 is bonded is in the meta-position,
and Z.sup.4 and Z.sup.5 are hydrogen atoms.
28. A method according to claim 19, wherein the nitrogen-containing
heteroaryl derivative is selected from any of the following, or
pharmacologically permitted salts thereof:
6-ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine,
N,N'-bis(3-hydroxyphenyl)-6-propyl-1,3,5-triazine-2,4-diamine,
6-isobutyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine,
6-s-butyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine,
6-t-butyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine, and
6-ethyl-N,N'-bis(3-hydroxy-4-methylphenyl)-1,3,5-triazine-2,4-diamine.
29. A method according to claim 19 wherein the amyloidosis is
selected from the group consisting of Alzheimer's disease, type 2
diabetes, immunoglobulinic amyloidosis, reactive amyloidosis,
dialysis related amyloidosis, senile amyloidosis, cerebrovascular
amyloidosis, hereditary cerebral haemorrhage with amyloidosis,
Creutzfeldt-Jacob disease, bovine spongiform encephalitis(BSE),
scrapie, medullary carcinoma of the thyroid, insulinoma, localized
atrial amyloid, amyloidosis cutis, localized nodular amyloidosis
and familial amyloidosis.
30. A method according to claim 19 wherein the amyloidosis is
Alzheimer's disease.
Description
TECHNICAL FIELD
[0001] The present invention relates to preventives or remedies for
Alzheimer's disease and to amyloid protein fibril-formation
inhibitors which include at least one nitrogen-containing
heteroaryl compound or physiologically-permitted salt thereof as an
active ingredient.
[0002] Furthermore, the present invention also relates to
nitrogen-containing heteroaryl derivatives with specified
substituents which are valuable as preventives or remedies for
Alzheimer's disease, or as amyloid protein fibril-formation
inhibitors.
TECHNICAL BACKGROUND
[0003] .beta.-Amyloid protein (hereinafter referred to as A.beta.)
is a major structural component of the senile plaques strikingly
present in the brains of patients with Alzheimer's disease, and it
is an insoluble peptide comprising 39 to 43 amino, acids. It is
produced by enzymic cleavage from .beta.-amyloid protein precursor
protein.
[0004] From recent detailed pathological research into the brains
of patients with Alzheimer's disease it is reported that, in the
process of the occurrence of dementia, first of all there is a
build-up of A.beta. within the brain of the patient, which triggers
the formation of senile plaques, and after the passage of a
considerable number of years there occurs neurofibrillary
degeneration followed by neuronal degenerative loss [Anna Rev.
Neurosci., Vol. 12, 463 (1989)]
[0005] Furthermore, it is reported that A.beta. which comprises 40
amino acids (A.beta. 1-40) and its active central portion peptide
(A.beta. 25-35) cause degeneration and death of rat primary
hippocampal neurons in an in vitro experimental system and
specifically lower the cellular MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]
reduction capacity [see, respectively, Science, Vol. 250, 279
(1990) and J. Neurochem., Vol. 65, 2585 (1995)].
[0006] As examples of the cells exhibiting a lowering of the MTT
reduction capacity due to A.beta., there are foetal rat hippocampal
neurons, PC12 cells and HeLa cells, etc. Consequently, by measuring
activity in inhibiting this lowering of the MTT reduction capacity
due to A.beta. in such cells, it is possible to investigate
substances which inhibit the damaging action of A.beta. on nerve
cells.
[0007] Now, long-term potentiation (hereinafter referred to as LTP)
is a phenomenon in which, by hippocampal nerve fibre electrical
stimulation at high frequency for a short time, the synapse
reaction strength is increased over a prolonged period, and it is
regarded as a model for learning and memory. It is reported that,
in hippocampal sections, A.beta. has an LTP impairing action [J.
Neurosci. Res. Vol. 60, 65 (2000), Proc. Natl. Acad. Sci. USA, Vol.
95, 6448 (1998), etc]. Furthermore, it is reported that, in a
transgenic mouse overexpressing A.beta., LTP in the hippocampus is
inhibited compared to normal mouse and, in a learning behaviour
test, the memory and learning capacity are lowered [Science, Vol.
274 99(1996)].
[0008] Consequently, by investigating substances which inhibit LTP
impairment due to A.beta. in the hippocampus, it is possible to
investigate substances which lessen memory impairment caused by
A.beta..
[0009] A.beta. is regarded as at least one of the causes of the
occurrence of Alzheimer's disease, so a substance which inhibits
the impairment of nerve cells induced by A.beta. would be effective
as a preventive or remedy for Alzheimer's disease.
[0010] Examples of known compounds which suppress nerve cell
toxicity due to A.beta. are rifampicin [Biochem. Biophys. Res.
Commun., Vol. 204, 76 (1994)], Congo Red [Proc. Natl. Acad. Sci.
USA, Vol. 91, 12243 (1994) and AZ36041 [Biol. Pharm. Bull., Vol.
18, 1750 (1995), etc.
[0011] Moreover, (-)-huperzine A is an example of a compound
reported to suppress LTP impairment in the hippocampus due to
A.beta. [Neurosci. Lett. Vol. 275 (3): 187-190 (1999)].
[0012] Illnesses which are characterized by the extracellular
deposition in various organs and tissues of polymerized amyloid
protein which adopts a specific fibrillar structure are generally
classified as amyloidosis. The protein from which this amyloid is
composed is, for example, in Alzheimer's disease, A.beta. which is
deposited in the brain; in type 2 diabetes, it is amylin which is
deposited in the pancreas; in familial amyloid neuropathy, it is
serum prealbumin (transthyretin) which is deposited in the
peripheral nerves; it is immunoglobulin light chain-derived AL
protein in the case of amyloidosis accompanying primary and
multiple myeloma; and it is AA protein in the case of secondary
amyloidosis, etc. [See, for example, Sipe, J. D., Annu. Rev.
Biochem., Vol. 61, 947-97 (1992), etc.]
[0013] The fact that the amyloid protein in the course of
fibril-formation produces a .beta.-sheet structure is known to be a
characteristic common to many amyloid proteins. [See, for example,
Sipe, J. D., Annu. Rev. Biochem., Vol. 61, 947-97 (1992), etc.]
[0014] A.beta. is a typical amyloid protein, and it accumulates in
the brains of Alzheimer's disease patients, forming senile plaques.
Within the senile plaques, a .beta.-sheet structure is adopted and
fibril formation occurs, and there is known to be characteristic
staining by dyes such as thioflavin and Congo red which denote a
fibrillar structure. Furthermore, it is known that with the
adoption of the .beta.-sheet structure and fibril formation,
A.beta. shows toxicity to cultured nerve cells [Pike, C. J. et al,
J. Neurosci. Vol. 13, 1676-1687 (1993)]
[0015] It is also known that the amylin, which is the main
structural component of the amyloid protein deposited in the
pancreas in type 2 diabetes, adopts a .beta.-sheet structure and
forms fibrils, which show toxicity to pancreatic .beta.-cells
[Lorenzo, A. et al, Nature, Vol. 368, 756-760 (1994)].
[0016] It is reported that amyloid proteins such as A.beta. and
amylin both exhibit cytotoxicity by adopting a .beta.-sheet
structure and forming fibrils, and by lowering the cell MTT
reduction capacity. Consequently, it is thought that compounds
which inhibit this fibril formation by amyloid proteins like
A.beta. and amylin would inhibit their cell toxicity. Furthermore,
since the mechanism of such manifestation of cytotoxicity is common
to a number of amyloid proteins, it is believed that drugs which
inhibit the cytotoxicity of certain amyloid proteins and suppress
fibril-formation could also, inhibit cytotoxicity and
fibril-formation in other amyloid proteins.
[0017] Thus, as well as Alzheimer's disease and type 2 diabetes, by
suppressing fibril-formation of amyloid protein this will be
effective as a preventive or remedy for, for example,
immunoglobulinic amyloidosis, reactive amyloidosis, familial
amyloidosis, dialysis-related amyloidosis, senile amyloidosis,
cerebrovascular amyloidosis, hereditary cerebral haemorrhage with
amyloidosis, Creutzfeldt-Jakob disease, bovine spongiform
encephalitis (BSE), scrapie, medullary carcinoma of the thyroid,
insulinoma, localized atrial amyloid, amyloidosis cutis, localized
nodular amyloidosis and other types of amyloidosis, preferably for
Alzheimer's disease, type 2 diabetes, dialysis-related amyloidosis,
familial amyloidosis, Creutzfeldt-Jakob disease and BSE, and in
particular for Alzheimer's disease or type 2 diabetes.
[0018] Known examples of compounds which inhibit amyloid protein
fibril-formation include variant peptide (WO96/28471),
imino-aza-anthracyclinone derivatives derived from anthrazalone
(WO98/32754), thionaphthalene derivatives with a specific structure
(JP-A-9-95444) and isochroman compounds (JP-A-2000-198781). As
compounds which inhibit fibril-formation by A.beta. in particular
from amongst the amyloid proteins, there are known iA.beta.5 [Nat.
Med., Vol. 4, 822-826 (1998)], and PTI-00703 [Neurobiol. Aging,
Vol. 19 (Suppl 4) 1070 (1998). However, these compounds have a
structure which is completely different from the
nitrogen-containing heteroaryl compounds which are the effective
component of the amyloid protein fibril-formation inhibitors of the
present invention.
[0019] With regard to nitrogen-containing heteroaryls,
3-[[4-[(2-fluoro-5-methylphenyl)amino]-2-pyrimidinyl]amino]-phenol
and 4-[[6-[(2,5-dichlorophenyl)amino]-4-pyrimidinyl]amino]-phenol
are disclosed as having an anticancer action (WO00/12485,
WO00/12486, etc), and the analogous 4,6-dianilino-pyrimidine
derivatives are also disclosed as having an anticancer action
(Japanese Patent Publication (PTC) No. 9-506363). Moreover,
4,4'-[(6-methyl-2,4-pyrimidinediyl)diimino]bisphenol,
4,4'-[(6-amino-1,3,5-triazine-2,4-diyl)diimino]bisphenol and
4,4'-[2,4-pyrimidinediyldiimino]bisphenol are disclosed as having
an antibacterial action, or anti-HIV action [J. Indian Chem. Soc.
Vol. 58 [5], 512-13 (1981), Acta Cienc. Indica. Chem. Vol. 11[1],
66-70 (1985), J. Med. Chem. Vol. 9(3), 423-4, (1966), WO99/36410,
WO99/50250].
[0020] Moreover, it has been disclosed that triazine derivatives
with a 4-position derivative have an impeding action for kinase
which is an enzyme catalysing the reaction to produce ATP by
transfer of a phosphoryl group within the cell, and are valuable in
the treatment of Alzheimer's disease, etc (WO01/25220).
DISCLOSURE OF THE INVENTION
[0021] The present inventors have carried out a painstaking study
with the objective of developing preventives or remedies for
Alzheimer's disease which have powerful activity and are highly
safe, and they have discovered that nitrogen-containing heteroaryl
compounds have an outstanding action in inhibiting the lowering of
MTT reduction capacity and in inhibiting long-term potentiation
impairment in the hippocampus, and are useful as preventives or
remedies for Alzheimer's disease. The present invention has been
perfected based on this discovery.
[0022] Furthermore, the present inventors have also carried out a
painstaking study with the objective of developing highly active
and highly safe drugs which can suppress amyloid protein
fibril-formation and can suppress cytotoxicity brought about by the
amyloid protein, and they have discovered that nitrogen-containing
heteroaryl compounds have an outstanding inhibitory action in terms
of amyloid protein fibril-formation, and also have a fibrillar
amyloid protein breakdown action and are valuable as preventives or
remedies for amyloidosis, for example Alzheimer's disease and type
2 diabetes. The present invention has also been perfected based on
this discovery.
[0023] This invention provides preventives or remedies for
Alzheimer's disease, or amyloid protein fibril-formation
inhibitors, which include at least one nitrogen-containing
heteroaryl compound, or pharmacologically permitted salt thereof,
as an active ingredient.
[0024] It also provides nitrogen-containing heteroaryl derivatives
which possess specified groups.
[0025] Specifically, the nitrogen-containing heteroaryl compounds
which are an active ingredient of the Alzheimer's disease
preventives or remedies, or of the amyloid protein fibril-formation
inhibitors, of the present invention, have the following general
formula (I).
##STR00002##
[0026] In this formula,
[0027] R.sup.1 and R.sup.2 each independently represent a hydrogen
atom or a C.sub.1-6 alkyl group,
[0028] Z.sup.1 and Z.sup.2 each independently represent a hydrogen
atom, C.sub.1-6 alkyl group, C.sub.1-6 alkoxy group, halo-C.sub.1-6
alkyl group or halogen atom,
[0029] Z.sup.3 represents a C.sub.1-6 alkoxy group, mercapto group,
C.sub.1-6 alkylthio group, amino group, mono- or di-C.sub.1-6
alkylamino group, hydroxy group or halogen atom,
[0030] Z.sup.4 and Z.sup.5 each independently represent a hydrogen
atom or halogen atom, and
[0031] A represents a group of formula (II) to (VI) below.
##STR00003##
[0032] In formulae (II) to (VI) above,
[0033] R.sup.3 represents a hydrogen atom, C.sub.1-6 alkyl group,
C.sub.1-6 alkoxy group, mercapto group, C.sub.1-6 alkylthio group,
amino group, mono- or di-C.sub.1-6 alkylamino group or hydroxy
group,
[0034] R.sup.4 represents a hydrogen atom or nitro group,
[0035] R.sup.5 represents a hydrogen atom or C.sub.1-6 alkyl
group,
[0036] R.sup.6 represents a hydrogen atom, C.sub.1-6 alkyl group,
C.sub.1-6 alkoxy group, mercapto group, C.sub.1-6 alkylthio group,
amino group, mono- or di-C.sub.1-6 alkylamino group or hydroxy
group,
[0037] R.sup.7 and R.sup.8 each independently represent a hydrogen
atom, C.sub.1-6 alkyl group, C.sub.1-6 alkoxy group, mercapto
group, C.sub.1-6 alkylthio group, amino group or mono- or
di-C.sub.1-6 alkylamino group,
[0038] R.sup.9 represents a C.sub.1-6 alkyl group, C.sub.1-6 alkoxy
group, mercapto group, C.sub.1-6 alkylthio group, amino group,
mono- or di-C.sub.1-6 alkylamino group or hydroxy group, and
[0039] R.sup.10 and R.sup.11 each independently represent a
hydrogen atom, C.sub.1-6 alkyl group, C.sub.1-6 alkoxy group,
C.sub.1-6 alkylthio group, or mono- or di-C.sub.1-6 alkylamino
group.
[0040] Furthermore, amongst the compounds (I), the
nitrogen-containing heteroaryl derivatives of the following general
formula (VII) below
##STR00004##
[0041] or general formula (VIII) below
##STR00005##
[0042] are novel compounds.
[0043] In the above formulae, R.sup.1, R.sup.2, R.sup.3, Z.sup.1,
Z.sup.2, Z.sup.5 and A have the same meanings as above, and Z.sup.6
represents a C.sub.1-C.sub.6 alkoxy group or a halogen atom.
[0044] The "C.sub.1-C.sub.6 alkyl group" denoted by R.sup.1,
R.sup.2, R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9,
R.sup.10, R.sup.11, Z.sup.1, and Z.sup.2, or the C.sub.1-C.sub.6
alkyl portion of the "C.sub.1-C.sub.6 alkoxy group" denoted by
R.sup.3, R.sup.7, R.sup.8, R.sup.9, Z.sup.1, Z.sup.2, Z.sup.3 and
Z.sup.6 may be, for example, a methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, s-butyl, t-butyl, pentyl, 1-methylbutyl,
2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl,
1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl,
1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl,
1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl,
2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl,
1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl or
1,2,2-trimethylpropyl group. Excepting the alkyl group and the
alkyl portion of the alkoxy group in the definitions of R.sup.1,
R.sup.2, R.sup.3, R.sup.9, R.sup.10 and R.sup.11, and the alkyl
portion of the alkoxy group in the definitions of R.sup.6 and
Z.sup.3, it is preferably a C.sub.1-4 alkyl group, more preferably
a methyl or ethyl group, and in particular a methyl group.
[0045] The alkyl group and the alkyl portion of the alkoxy {sic}
group in the definitions of R.sup.1 and R.sup.2 are preferably a
methyl or ethyl group.
[0046] The alkyl group in the definition of R.sup.3 is preferably a
C.sub.1-5 alkyl group, more preferably a C.sub.1-4 alkyl group, and
still more preferably an ethyl, propyl or isopropyl group. The
alkyl portion of the alkoxy group in the definition of R.sup.3 is
preferably a C.sub.1-4 alkyl group and more preferably a C.sub.1-3
alkyl group.
[0047] The alkyl portion of the alkoxy group in the definition of
R.sup.6 is preferably a C.sub.1-3 alkyl group, and more preferably
a methyl or ethyl group.
[0048] The alkyl group in the definition of R.sup.9 is preferably a
C.sub.1-5 alkyl group, more preferably a C.sub.2-4 alkyl group and
still more preferably an ethyl, propyl, isobutyl, s-butyl or
t-butyl group. The alkyl portion of the alkoxy group in the
definition of R.sup.9 is preferably a C.sub.1-4 alkyl group, more
preferably a methyl, ethyl or butyl group, and in particular a
butyl group.
[0049] The alkyl group and the alkyl portion of the alkoxy group in
the definitions of R.sup.10 and R.sup.11 are preferably a C.sub.1-3
alkyl group.
[0050] The alkyl portion of the alkoxy group in the definition of
Z.sup.3 is preferably a C.sub.1-3 alkyl group.
[0051] The "halogen atom" in the definitions of Z.sup.1, Z.sup.2,
Z.sup.3, Z.sup.4, Z.sup.5 and Z.sup.6 is for example a fluorine,
chlorine, bromine or iodine atom, preferably a fluorine or chlorine
atom, and in particular a chlorine atom.
[0052] The C.sub.1-6 alkyl portion of the "halo-C.sub.1-6 alkyl
group" in the definitions of Z.sup.1 and Z.sup.2 is the same as in
the case of the C.sub.1-6 alkyl group above, and the halogen
portion is the same as the halogen atom above. Examples are the
fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,
dichloromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl,
1,1-difluoroethyl, 1,2-difluoroethyl, 1-chloroethyl, 2-chloroethyl,
1,1-dichloroethyl and 1,2-dichloroethyl group, with the
fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,
dichloromethyl, trichloromethyl, 1-fluoroethyl and 1-chloroethyl
group being preferred, and the trifluoromethyl group further
preferred.
[0053] The C.sub.1-6 alkyl portion of the "C.sub.1-6 alkylthio
group" in the definitions of R.sup.3, R.sup.6, R.sup.7, R.sup.8,
R.sup.9, R.sup.10, R.sup.11 and Z.sup.3 is the same as the
C.sub.1-6 alkyl group above, and examples are methylthio,
ethylthio, propylthio, isopropylthio, butylthio, isobutylthio,
s-butylthio and t-butylthio.
[0054] Excluding the alkyl portion of the thioalkyl group in the
definitions of R.sup.3, R.sup.6, R.sup.10, R.sup.11 and Z.sup.3, a
C.sub.1-4 alkylthio is preferred, more preferably the methylthio or
ethylthio group, and in particular the methylthio group.
[0055] With regard to the alkyl portion of the thioalkyl group in
the definitions of R.sup.3, R.sup.6, R.sup.10, R.sup.11 and
Z.sup.3, this is preferably a C.sub.1-3 alkyl group, with the
methylthio group being particularly preferred.
[0056] The C.sub.1-6 alkyl portion of the "mono- or di-C.sub.1-6
alkylamino group" in the definitions of R.sup.3, R.sup.6, R.sup.7,
R.sup.8, R.sup.9, R.sup.10, R.sup.11 and Z.sup.3 is the same as the
C.sub.1-6 alkyl group above, examples being the methylamino,
ethylamino, propylamino, dimethylamino, methylethylamino,
methylpropylamino, diethylamino, ethylpropylamino and dipropylamino
groups. Except in the case of R.sup.3 and R.sup.9, the methylamino,
ethylamino or dimethylamino group is preferred, with the
methylamino group particularly preferred. With regard to the mono-
or di-alkylamino group in the definitions of R.sup.3 and R.sup.9, a
mono- or di-C.sub.1-3 alkylamino group is preferred, and
methylamino or dimethylamino is further preferred.
[0057] Z.sup.3 is preferably a C.sub.1-4 alkoxy group, C.sub.1-4
alkylthio group or hydroxy group, more preferably a C.sub.1-2
alkoxy group, C.sub.1-2 alkylthio group or hydroxy group, with a
hydroxy group particularly preferred.
[0058] In the case of the compounds of the present invention
represented by general formula (I) or (VII) above, the following
preferred compounds can be cited.
[0059] 1) The compounds where R.sup.1 and R.sup.2 are each
independently a hydrogen atom or a C.sub.1-2 alkyl group,
[0060] 2) The compounds where R.sup.1 and R.sup.2 are hydrogen
atoms,
[0061] 3) The compounds where A is a group represented by formula
(II) (where R.sup.3 is a hydrogen atom, C.sub.1-5 alkyl, C.sub.1-3
alkylthio or mono- or di-C.sub.1-3 alkylamino group, and R.sup.4 is
a hydrogen atom or nitro group), a group represented by formula
(III) (where R.sup.5 and R.sup.6 are each independently a hydrogen
atom or C.sub.1-2 alkyl group), a group of formula (IV) (where
R.sup.7 and R.sup.8 are each independently a hydrogen atom or
C.sub.1-2 alkyl group), a group of formula (V) (where R.sup.9 is a
C.sub.1-5 alkyl, C.sub.1-4 alkoxy or a C.sub.1-4 alkylthio group),
or a group of formula (VI) (where R.sup.10 and R.sup.11 are each
independently a hydrogen atom or C.sub.1-3 alkyl group),
[0062] 4) The compounds where A is a group of formula (II) (where
R.sup.3 is a hydrogen atom, C.sub.1-5 alkyl, C.sub.1-3 alkylthio or
mono- or di-C.sub.1-3 alkylamino group, and R.sup.4 is a hydrogen
atom or nitro group), a group of formula (III) (where R.sup.5 is a
hydrogen atom and R.sup.6 is a methyl or ethyl group), a group of
formula (IV) (where R.sup.7 and R.sup.8 are hydrogen atoms), a
group of formula (V) (where R.sup.9 is a C.sub.1-5 alkyl, C.sub.1-4
alkoxy or C.sub.1-4 alkylthio group), or a group of formula (VI)
(where R.sup.10 and R.sup.11 are hydrogen atoms),
[0063] 5) The compounds where A is a group of formula (II) (where
R.sup.3 is a hydrogen atom, C.sub.1-4 alkyl or amino group, and
R.sup.4 is a hydrogen atom or nitro group) or a group of formula
(V) (where R.sup.9 is a C.sub.2-4 alkyl or a butoxy group),
[0064] 6) The compounds where A is a group of formula (II) (where
R.sup.3 is an ethyl, propyl, isopropyl or amino group and R.sup.4
is a hydrogen atom, or R.sup.3 is a hydrogen atom and R.sup.4 is a
nitro group) or a group of formula (V) (where R.sup.9 is a
C.sub.2-4 alkyl group),
[0065] 7) The compounds where Z.sup.1 and Z.sup.2 are each
independently a hydrogen atom or para-position fluorine atom,
chlorine atom or C.sub.1-2 alkyl group, [0066] Z.sup.3 is a
meta-position hydroxy group (in the case of compound (I)), or the
hydroxy group on the phenyl ring to which Z.sup.1 is bonded is in
the meta-position (in the case of compound (VII)) and [0067]
Z.sup.4 and Z.sup.5 are hydrogen atoms,
[0068] 8) The compounds where Z.sup.1 and Z.sup.2 are each a
hydrogen atom or para-position methyl group, [0069] Z.sup.3 is a
meta-position hydroxy group (in the case of compound (I), or the
hydroxy group on the phenyl ring to which Z.sup.1 is bonded is in
the meta-position (in the case of compound (VII)), and [0070]
Z.sup.4 and Z.sup.5 are hydrogen atoms.
[0071] Taking these together, for example combinations of 2), 3) to
6) and 8) are preferred. Amongst these combinations, the
combination of 2), 6) and 8) is further preferred.
[0072] Moreover, in the case of the compounds (VIII), there can be
cited
[0073] 1) the compounds where R.sup.1 and R.sup.2 are each
independently a hydrogen atom or C.sub.1-2 alkyl group,
[0074] 2) the compounds where R.sup.1 and R.sup.2 are hydrogen
atoms,
[0075] 3) the compounds where R.sup.3 is a hydrogen atom, C.sub.1-5
alkyl, C.sub.1-3 alkylthio, mono- or di-C.sub.1-3 alkylamino group
or amino group,
[0076] 4) the compounds where R.sup.3 is a hydrogen atom, C.sub.1-4
alkyl or amino group,
[0077] 5) the compounds where R.sup.3 is an ethyl, propyl,
isopropyl or amino group,
[0078] 6) the compounds where Z.sup.6 is a C.sub.1-4 alkoxy group,
fluorine atom or chlorine atom, and
[0079] 7) the compounds where Z.sup.6 is a methoxy group, ethoxy
group or chlorine atom.
[0080] Taking these together, for example combinations of 2), 3) to
5) and 7) are preferred. Amongst these combinations, the
combination of 2), 5) and 7) is further preferred.
[0081] The compounds of the present invention of general formula
(I), (VII) or (VIII) possess within the same molecule a phenolic
hydroxy group, which is a weakly acidic group, and an amino group
or alkylamino group, etc, which is a weakly basic group, so they
form physiologically permitted salts when reacted with a
comparatively strong base or acid. Examples of such salts are the
salts with a base, such as alkali metal salts like the lithium
salt, sodium salt and potassium salt, alkaline earth metal salts
like the magnesium salt, calcium salt and barium salt, and amino
acid salts like the glycine salt, lysine arginine salt, ornithine
salt, glutamic acid salt and aspartic acid salt. The alkali metal
salts are preferred (in particular the sodium salt).
[0082] Furthermore, examples of the salts with an acid are mineral
acid salts like hydrohalide salts such as the hydrochloride,
hydrobromide and hydroiodide, the nitrate, perchlorate, sulphate,
phosphate and carbonate, sulphonic acid salts like the
methanesulphonate, tri fluoromethanesulphonate, ethanesulphonate,
benzenesulphonate and toluenesulphonate, and carboxylic acid salts
such as the acetate, fumarate and maleate. The hydrochloride,
nitrate, sulphate and phosphate are preferred.
[0083] Moreover, where the compounds of the present invention and
their pharmacologically permitted salts form solvates (such as
hydrates), then these too are included within the scope of the
invention.
[0084] Tables 1 to 5 below give specific examples of preferred
compounds represented by aforesaid general formulae (I), (VII) or
(VIII). The compounds shown in Tables 1 to 5 have the formulae
denoted by (1) to (5) respectively.
[0085] With regard to the abbreviations employed below, Me means
the methyl group, Et means the ethyl group, Pr means the propyl
group, iPr means the isopropyl group, Bu means the butyl group, iBu
means the isobutyl group, sBu means the s-butyl group, tBu means
the t-butyl group, Pn means the pentyl group and Hx means the hexyl
group.
[0086] The compounds of the following general formula
##STR00006##
[0087] [where R.sup.x, R.sup.y and R.sup.z are the same or
different, and each represent a hydrogen atom or a C.sub.1-4 alkyl
group (preferably R.sup.x, R.sup.y and R.sup.z are the same or
different, and each represent a hydrogen atom or a methyl group;
more preferably, R.sup.x, R.sup.y and R.sup.z are methyl groups),
and n is 1 or 2 (preferably 2)] are known compounds (see, for
example, JP-A-5-32654), and possess an outstanding action in
inhibiting a lowering of the MTT reduction capacity and in
inhibiting LTP impairment in the hippocampus, and they are valuable
as Alzheimer's disease preventives or remedies.
TABLE-US-00001 TABLE 1 (1) ##STR00007## Exemplified Compound No.
R.sup.1 R.sup.2 R.sup.3 R.sup.4 Z.sup.1 Z.sup.2 Z.sup.3 Z.sup.4
Z.sup.5 1-1 H H H H H H 3-OH H H 1-2 H H Me H H H 3-OH H H 1-3 H H
Et H H H 3-OH H H 1-4 H H Pr H H H 3-OH H H 1-5 H H iPr H H H 3-OH
H H 1-6 H H Bu H H H 3-OH H H 1-7 H H iBu H H H 3-OH H H 1-8 H H
sBu H H H 3-OH H H 1-9 H H tBu H H H 3-OH H H 1-10 H H OH H H H
3-OH H H 1-11 H H OMe H H H 3-OH H H 1-12 H H OEt H H H 3-OH H H
1-13 H H OPr H H H 3-OH H H 1-14 H H OiPr H H H 3-OH H H 1-15 H H
OBu H H H 3-OH H H 1-16 H H OiBu H H H 3-OH H H 1-17 H H OsBu H H H
3-OH H H 1-18 H H OtBu H H H 3-OH H H 1-19 H H SH H H H 3-OH H H
1-20 H H SMe H H H 3-OH H H 1-21 H H SEt H H H 3-OH H H 1-22 H H
NH.sub.2 H H H 3-OH H H 1-23 H H NHMe H H H 3-OH H H 1-24 H H
NMe.sub.2 H H H 3-OH H H 1-25 H H NMeEt H H H 3-OH H H 1-26 H H
NEt.sub.2 H H H 3-OH H H 1-27 H Me H H H H 3-OH H H 1-28 Me Me H H
H H 3-OH H H 1-29 H Me Me H H H 3-OH H H 1-30 H Et Me H H H 3-OH H
H 1-31 Me Me Me H H H 3-OH H H 1-32 H Me Et H H H 3-OH H H 1-33 H
Et Et H H H 3-OH H H 1-34 Me Me Et H H H 3-OH H H 1-35 Et Et Et H H
H 3-OH H H 1-36 H Me Pr H H H 3-OH H H 1-37 H Et Pr H H H 3-OH H H
1-38 Me Me Pr H H H 3-OH H H 1-39 Et Et Pr H H H 3-OH H H 1-40 H Me
iPr H H H 3-OH H H 1-41 H Et iPr H H H 3-OH H H 1-42 Me Me iPr H H
H 3-OH H H 1-43 Et Et iPr H H H 3-OH H H 1-44 H Me Bu H H H 3-OH H
H 1-45 H Et Bu H H H 3-OH H H 1-46 Me Me Bu H H H 3-OH H H 1-47 Et
Et Bu H H H 3-OH H H 1-48 H Me iBu H H H 3-OH H H 1-49 Me Me iBu H
H H 3-OH H H 1-50 H Me sBu H H H 3-OH H H 1-51 Me Me sBu H H H 3-OH
H H 1-52 H Me tBu H H H 3-OH H H 1-53 Me Me tBu H H H 3-OH H H 1-54
H Me OH H H H 3-OH H H 1-55 Me Me OH H H H 3-OH H H 1-56 H Me OMe H
H H 3-OH H H 1-57 Me Me OMe H H H 3-OH H H 1-58 H Me OEt H H H 3-OH
H H 1-59 Me Me OEt H H H 3-OH H H 1-60 H Me OPr H H H 3-OH H H 1-61
Me Me OPr H H H 3-OH H H 1-62 H Me OiPr H H H 3-OH H H 1-63 Me Me
OiPr H H H 3-OH H H 1-64 H Me SH H H H 3-OH H H 1-65 H Et SH H H H
3-OH H H 1-66 Me Me SH H H H 3-OH H H 1-67 Et Et SH H H H 3-OH H H
1-68 H Me SMe H H H 3-OH H H 1-69 H Et SMe H H H 3-OH H H 1-70 Me
Me SMe H H H 3-OH H H 1-71 Et Et SMe H H H 3-OH H H 1-72 H Me SEt H
H H 3-OH H H 1-73 Me Me SEt H H H 3-OH H H 1-74 H Me NH.sub.2 H H H
3-OH H H 1-75 H Et NH.sub.2 H H H 3-OH H H 1-76 Me Me NH.sub.2 H H
H 3-OH H H 1-77 Et Et NH.sub.2 H H H 3-OH H H 1-78 H Me NHMe H H H
3-OH H H 1-79 Me Me NHMe H H H 3-OH H H 1-80 H Me NMe.sub.2 H H H
3-OH H H 1-81 Me Me NMe.sub.2 H H H 3-OH H H 1-82 H Me NMeEt H H H
3-OH H H 1-83 Me Me NMeEt H H H 3-OH H H 1-84 H Me NEt.sub.2 H H H
3-OH H H 1-85 Me Me NEt.sub.2 H H H 3-OH H H 1-86 H H H H 2-Me 2-Me
3-OH H H 1-87 H H H H 4-Me 4-Me 3-OH H H 1-88 H H H H 4-OMe 4-OMe
3-OH H H 1-89 H H Me H 4-Me 4-Me 3-OH H H 1-90 H H Me H 5-CF.sub.3
5-CF.sub.3 3-OH H H 1-91 H H Et H 4-Me 4-Me 3-OH H H 1-92 H H Pr H
4-Me 4-Me 3-OH H H 1-93 H H iPr H 4-Me 4-Me 3-OH H H 1-94 H H Bu H
4-Me 4-Me 3-OH H H 1-95 H H iBu H 4-Me 4-Me 3-OH H H 1-96 H H sBu H
4-Me 4-Me 3-OH H H 1-97 H H tBu H 4-Me 4-Me 3-OH H H 1-98 H H OH H
4-Me 4-Me 3-OH H H 1-99 H H SH H 4-Me 4-Me 3-OH H H 1-100 H H SMe H
4-Me 4-Me 3-OH H H 1-101 H H SEt H 4-Me 4-Me 3-OH H. H 1-102 H H
NH.sub.2 H 4-Me 4-Me 3-OH H H 1-103 H H NHMe H 4-Me 4-Me 3-OH H H
1-104 H H NMe.sub.2 H 4-Me 4-Me 3-OH H H 1-105 H H NMeEt H 4-Me
3-OH 3-OH H H 1-106 H H NEt.sub.2 H 4-Me 4-Me 3-OH H H 1-107 H H H
H H H 3-OMe H H 1-108 H H Me H H H 3-OMe H H 1-109 H H Et H H H
3-OMe H H 1-110 H H Pr H H H 3-OMe H H 1-111 H H iPr H H H 3-OMe H
H 1-112 H H Bu H H H 3-OMe H H 1-113 H H OH H H H 3-OMe H H 1-114 H
H H H H H 3-OEt H H 1-115 H H Me H H H 3-OEt H H 1-116 H H Et H H H
3-OEt H H 1-117 H H Pr H H H 3-OEt H H 1-118 H H iPr H H H 3-OEt H
H 1-119 H H Bu H H H 3-OEt H H 1-120 H H H H H H 3-OPr H H 1-121 H
H Me H H H 3-OPr H H 1-122 H H Et H H H 3-OPr H H 1-123 H H Pr H H
H 3-OPr H H 1-124 H H iPr H H H 3-OPr H H 1-125 H H Bu H H H 3-OPr
H H 1-126 H H OH H H H 3-OPr H H 1-127 H H H H H H 3-SH H H 1-128 H
H Me H H H 3-SH H H 1-129 H H Et H H H 3-SH H H 1-130 H H Pr H H H
3-SH H H 1-131 H H iPr H H H 3-SH H H 1-132 H H Bu H H H 3-SH H H
1-133 H H OH H H H 3-SH H H 1-134 H H H H H H 3-SMe H H 1-135 H H
Me H H H 3-SMe H H 1-136 H H Et H H H 3-SMe H H 1-137 H H Pr H H H
3-SMe H H 1-138 H H iPr H H H 3-SMe H H 1-139 H H Bu H H H 3-SMe H
H 1-140 H H OH H H H 3-SMe H H 1-141 H H Et H H H 3-SEt H H 1-142 H
H Pr H H H 3-SEt H H 1-143 H H OH H H H 3-SEt H H 1-144 H H Et H H
H 3-SPr H H 1-145 H H Pr H H H 3-SPr H H 1-146 H H OH H H H 3-SPr H
H 1-147 H H H H H H 3-NH.sub.2 H H 1-148 H H Me H H H 3-NH.sub.2 H
H 1-149 H H Et H H H 3-NH.sub.2 H H 1-150 H H Pr H H H 3-NH.sub.2 H
H 1-151 H H OH H H H 3-NH.sub.2 H H 1-152 H H Et H H H 3-NHMe H H
1-153 H H Pr H H H 3-NHMe H H 1-154 H H OH H H H 3-NHMe H H 1-155 H
H Et H H H 3-NHEt H H 1-156 H H Pr H H H 3-NHEt H H 1-157 H H OH H
H H 3-NHEt H H 1-158 H H H H H H 3-F H H 1-159 H H H H H H 3-Cl H H
1-160 H H Me H H H 3-F H H 1-161 H H Me H H H 3-Cl H H 1-162 H H Pr
H H H 3-F H H 1-163 H H Pr H H H 3-Cl H H 1-164 H H iPr H H H 3-F H
H 1-165 H H iPr H H H 3-Cl H H 1-166 H H Bu H H H 3-F H H 1-167 H H
Bu H H H 3-Cl H H 1-168 H H OH H H H 3-Cl H H 1-169 H H H H 4-F 4-F
3-OH 6-F 6-F 1-170 H H H H 4-Cl 4-Cl 3-OH 6-Cl 6-Cl 1-171 H H Me H
4-F 4-F 3-OH 6-F 6-F 1-172 H H Me H 4-Cl 4-Cl 3-OH 6-Cl 6-Cl 1-173
H H H NO.sub.2 H H 3-OH H H 1-174 H Me H NO.sub.2 H H 3-OH H H
1-175 H Et H NO.sub.2 H H 3-OH H H 1-176 Me Me H NO.sub.2 H H 3-OH
H H 1-177 Et Et H NO.sub.2 H H 3-OH H H 1-178 H H Me NO.sub.2 H H
3-OH H H 1-179 H H Et NO.sub.2 H H 3-OH H H 1-180 H H Pr NO.sub.2 H
H 3-OH H H 1-181 H H iPr NO.sub.2 H H 3-OH H H 1-182 H H Bu
NO.sub.2 H H 3-OH H H 1-183 H H OH NO.sub.2 H H 3-OH H H 1-184 H H
OMe NO.sub.2 H H 3-OH H H 1-185 H H OEt NO.sub.2 H H 3-OH H H 1-186
H H OPr NO.sub.2 H H 3-OH H H 1-187 H H OiPr NO.sub.2 H H 3-OH H H
1-188 H H OBu NO.sub.2 H H 3-OH H H 1-189 H H SH NO.sub.2 H H 3-OH
H H 1-190 H H SMe NO.sub.2 H H 3-OH H H 1-191 H H SEt NO.sub.2 H H
3-OH H H 1-192 H H NH.sub.2 NO.sub.2 H H 3-OH H H 1-193 H H NHMe
NO.sub.2 H H 3-OH H H 1-194 H. H NMe.sub.2 NO.sub.2 H H 3-OH H H
1-195 H H NMeEt NO.sub.2 H H 3-OH H H 1-196 H H NEt.sub.2 NO.sub.2
H H 3-OH H H 1-197 H H Pn H H H 3-OH H H 1-198 H H 3-MeBu H H H
3-OH H H 1-199 H H Hx H H H 3-OH H H 1-200 H H H H H H 3-NHMe H H
1-201 H H Me H H H 3-NHMe H H 1-202 H H H H H H 3-NHEt H H 1-203 H
H Me H H H 3-NHEt H H 1-204 H H Et H H H 3-F H H 1-205 H H Et H H H
3-Cl H H 1-206 H H SPr H H H 3-OH H H 1-207 H H SiPr H H H 3-OH H H
1-208 H Me SPr H H H 3-OH H H 1-209 H Et SPr H H H 3-OH H H 1-210
Me Me SPr H H H 3-OH H H 1-211 Et Et SPr H H H 3-OH H H 1-212 H Me
SiPr H H H 3-OH H H 1-213 H Et SiPr H H H 3-OH H H 1-214 Me Me SiPr
H H H 3-OH H H 1-215 Et Et SiPr H H H 3-OH H H 1-216 H H OH H H H
3-OEt H H 1-217 H H H H H H 3-OiPr H H 1-218 H H Me H H H 3-OiPr H
H 1-219 H H Et H H H 3-OiPr H H 1-220 H H Pr H H H 3-OiPr H H 1-221
H H iPr H H H 3-OiPr H H 1-222 H H Bu H H H 3-OiPr H H 1-223 H H OH
H H H 3-OiPr H H
TABLE-US-00002 TABLE 2 (2) ##STR00008## Exemplified Compound No.
R.sup.1 R.sup.2 R.sup.5 R.sup.6 Z.sup.1 Z.sup.2 Z.sup.3 Z.sup.4
Z.sup.5 2-1 H H H H H H 3-OH H H 2-2 H Me H H H H 3-OH H H 2-3 H Et
H H H H 3-OH H H 2-4 Me Me H H H H 3-OH H H 2-5 Et Et H H H H 3-OH
H H 2-6 H H H Me H H 3-OH H H 2-7 H Me H Me H H 3-OH H H 2-8 H Et H
Me H H 3-OH H H 2-9 Me Me H Me H H 3-OH H H 2-10 Et Et H Me H H
3-OH H H 2-11 H H Me Me H H 3-OH H H 2-12 H Me Me Me H H 3-OH H H
2-13 H Et Me Me H H 3-OH H H 2-14 Me Me Me Me H H 3-OH H H 2-15 Et
Et Me Me H H 3-OH H H 2-16 H H Me Et H H 3-OH H H 2-17 H Me Me Et H
H 3-OH H H 2-18 H Et Me Et H H 3-OH H H 2-19 Me Me Me Et H H 3-OH H
H 2-20 Et Et Me Et H H 3-OH H H 2-21 H H Et Et H H 3-OH H H 2-22 H
Me Et Et H H 3-OH H H 2-23 H Et Et Et H H 3-OH H H 2-24 Me Me Et Et
H H 3-OH H H 2-25 Et Et Et Et H H 3-OH H H 2-26 H H H OH H H 3-OH H
H 2-27 H Me H OH H H 3-OH H H 2-28 H Et H OH H H 3-OH H H 2-29 Me
Me H OH H H 3-OH H H 2-30 Et Et H OH H H 3-OH H H 2-31 H H H OMe H
H 3-OH H H 2-32 H Me H OMe H H 3-OH H H 2-33 H Et H OMe H H 3-OH H
H 2-34 Me Me H OMe H H 3-OH H H 2-35 Et Et H OMe H H 3-OH H H 2-36
H H H OEt H H 3-OH H H 2-37 H Me H OEt H H 3-OH H H 2-38 H Et H OEt
H H 3-OH H H 2-39 Me Me H OEt H H 3-OH H H 2-40 Et Et H OEt H H
3-OH H H 2-41 H H H OPr H H 3-OH H H 2-42 H Me H OPr H H 3-OH H H
2-43 H Et H OPr H H 3-OH H H 2-44 Me Me H OPr H H 3-OH H H 2-45 Et
Et H OPr H H 3-OH H H 2-46 H H H OiPr H H 3-OH H H 2-47 H Me H OiPr
H H 3-OH H H 2-48 H Et H OiPr H H 3-OH H H 2-49 Me Me H OiPr H H
3-OH H H 2-50 Et Et H OiPr H H 3-OH H H 2-51 H H H SH H H 3-OH H H
2-52 H Me H SH H H 3-OH H H 2-53 H Et H SH H H 3-OH H H 2-54 Me Me
H SH H H 3-OH H H 2-55 Et Et H SH H H 3-OH H H 2-56 H H H SMe H H
3-OH H H 2-57 H Me H SMe H H 3-OH H H 2-58 H Et H SMe H H 3-OH H H
2-59 Me Me H SMe H H 3-OH H H 2-60 Et Et H SMe H H 3-OH H H 2-61 H
H H SEt H H 3-OH H H 2-62 H Me H SEt H H 3-OH H H 2-63 H Et H SEt H
H 3-OH H H 2-64 Me Me H SEt H H 3-OH H H 2-65 Et Et H SEt H H 3-OH
H H 2-66 H H H SPr H H 3-OH H H 2-67 H Me H SPr H H 3-OH H H 2-68 H
Et H SPr H H 3-OH H H 2-69 Me Me H SPr H H 3-OH H H 2-70 Et Et H
SPr H H 3-OH H H 2-71 H H H SiPr H H 3-OH H H 2-72 H Me H SiPr H H
3-OH H H 2-73 H Et H SiPr H H 3-OH H H 2-74 Me Me H SiPr H H 3-OH H
H 2-75 Et Et H SiPr H H 3-OH H H 2-76 H H H NH.sub.2 H H 3-OH H H
2-77 H Me H NH.sub.2 H H 3-OH H H 2-78 H Et H NH.sub.2 H H 3-OH H H
2-79 Me Me H NH.sub.2 H H 3-OH H H 2-80 Et Et H NH.sub.2 H H 3-OH H
H 2-81 H H H NHMe H H 3-OH H H 2-82 H Me H NHMe H H 3-OH H H 2-83 H
Et H NHMe H H 3-OH H H 2-84 Me Me H NHMe H H 3-OH H H 2-85 Et Et H
NHMe H H 3-OH H H 2-86 H H H NMe.sub.2 H H 3-OH H H 2-87 H Me H
NMe.sub.2 H H 3-OH H H 2-88 H Et H NMe.sub.2 H H 3-OH H H 2-89 Me
Me H NMe.sub.2 H H 3-OH H H 2-90 Et Et H NMe.sub.2 H H 3-OH H H
2-91 H H H NMeEt H H 3-OH H H 2-92 H Me H NMeEt H H 3-OH H H 2-93 H
Et H NMeEt H H 3-OH H H 2-94 Me Me H NMeEt H H 3-OH H H 2-95 Et Et
H NMeEt H H 3-OH H H 2-96 H H H NEt.sub.2 H H 3-OH H H 2-97 H Me H
NEt.sub.2 H H 3-OH H H 2-98 H Et H NEt.sub.2 H H 3-OH H H 2-99 Me
Me H NEt.sub.2 H H 3-OH H H 2-100 Et Et H NEt.sub.2 H H 3-OH H H
2-101 H H H H 2-Me 2-Me 3-OH H H 2-102 H H H H 4-Me 4-Me 3-OH H H
2-103 H H H Me 4-Me 4-Me 3-OH H H 2-104 H H H Et 4-Me 4-Me 3-OH H H
2-105 H H Me Me 4-Me 4-Me 3-OH H H 2-106 H H Et Et 4-Me 4-Me 3-OH H
H 2-107 H H H NHEt H H 3-OH H H 2-108 H Me H NHEt H H 3-OH H H
2-109 H Et H NHEt H H 3-OH H H 2-110 Me Me H NHEt H H 3-OH H H
2-111 Et Et H NHEt H H 3-OH H H
TABLE-US-00003 TABLE 3 (3) ##STR00009## Exemplified Compound Number
R.sup.1 R.sup.2 R.sup.7 R.sup.8 Z.sup.1 Z.sup.2 Z.sup.3 Z.sup.4
Z.sup.5 3-1 H H H H H H 3-OH H H 3-2 H Me H H H H 3-OH H H 3-3 H Et
H H H H 3-OH H H 3-4 Me Me H H H H 3-OH H H 3-5 Et Et H H H H 3-OH
H H 3-6 H H Me H H H 3-OH H H 3-7 H Me Me H H H 3-OH H H 3-8 H Et
Me H H H 3-OH H H 3-9 Me Me Me H H H 3-OH H H 3-10 Et Et Me H H H
3-OH H H 3-11 H H Me Me H H 3-OH H H 3-12 H Me Me Me H H 3-OH H H
3-13 H Et Me Me H H 3-OH H H 3-14 Me Me Me Me H H 3-OH H H 3-15 Et
Et Me Me H H 3-OH H H 3-16 H H Me Et H H 3-OH H H 3-17 H Me Me Et H
H 3-OH H H 3-18 H Et Me Et H H 3-OH H H 3-19 Me Me Me Et H H 3-OH H
H 3-20 Et Et Me Et H H 3-OH H H 3-21 H H Et Et H H 3-OH H H 3-22 H
Me Et Et H H 3-OH H H 3-23 H Et Et Et H H 3-OH H H 3-24 Me Me Et Et
H H 3-OH H H 3-25 Et Et Et Et H H 3-OH H H 3-26 H H H H 4-Me 4-Me
3-OH H H 3-27 H H H Me 4-Me 4-Me 3-OH H H 3-28 H H Me Me 4-Me 4-Me
3-OH H H 3-29 H H Me Et 4-Me 4-Me 3-OH H H 3-30 H H Et Et 4-Me 4-Me
3-OH H H 3-31 H H H H 4-Et 4-Et 3-OH H H 3-32 H H H Me 4-Et 4-Et
3-OH H H 3-33 H H Me Me 4-Et 4-Et 3-OH H H 3-34 H H Me Et 4-Et 4-Et
3-OH H H 3-35 H H Et Et 4-Et 4-Et 3-OH H H 3-36 H H H H H H 3-OMe H
H 3-37 H H H H H H 3-OEt H H 3-38 H H H H H H 3-OPr H H 3-39 H H H
H H H 3-SH H H 3-40 H H H H H H 3-SMe H H 3-41 H H H H H H 3-SEt H
H 3-42 H H H H H H 3-SPr H H 3-43 H H H H H H 3-NH.sub.2 H H 3-44 H
H H H H H 3-OiPr H H
TABLE-US-00004 TABLE 4 (4) ##STR00010## Exemplified Compound No.
R.sup.1 R.sup.2 R.sup.9 Z.sup.1 Z.sup.2 Z.sup.3 Z.sup.4 Z.sup.5 4-1
H H Me H H 3-OH H H 4-2 H Me Me H H 3-OH H H 4-3 H Et Me H H 3-OH H
H 4-4 Me Me Me H H 3-OH H H 4-5 Et Et Me H H 3-OH H H 4-6 H H Et H
H 3-OH H H 4-7 H Me Et H H 3-OH H H 4-8 H Et Et H H 3-OH H H 4-9 Me
Me Et H H 3-OH H H 4-10 Et Et Et H H 3-OH H H 4-11 H H Pr H H 3-OH
H H 4-12 H Me Pr H H 3-OH H H 4-13 H Et Pr H H 3-OH H H 4-14 Me Me
Pr H H 3-OH H H 4-15 Et Et Pr H H 3-OH H H 4-16 H H iPr H H 3-OH H
H 4-17 H Me iPr H H 3-OH H H 4-18 H Et iPr H H 3-OH H H 4-19 Me Me
iPr H H 3-OH H H 4-20 Et Et iPr H H 3-OH H H 4-21 H H Bu H H 3-OH H
H 4-22 H Me Bu H H 3-OH H H 4-23 H Et Bu H H 3-OH H H 4-24 Me Me Bu
H H 3-OH H H 4-25 Et Et Bu H H 3-OH H H 4-26 H H iBu H H 3-OH H H
4-27 H Me iBu H H 3-OH H H 4-28 H Et iBu H H 3-OH H H 4-29 Me Me
iBu H H 3-OH H H 4-30 Et Et iBu H H 3-OH H H 4-31 H H sBu H H 3-OH
H H 4-32 H Me sBu H H 3-OH H H 4-33 H Et sBu H H 3-OH H H 4-34 Me
Me sBu H H 3-OH H H 4-35 Et Et sBu H H 3-OH H H 4-36 H H tBu H H
3-OH H H 4-37 H Me tBu H H 3-OH H H 4-38 H Et tBu H H 3-OH H H 4-39
Me Me tBu H H 3-OH H H 4-40 Et Et tBu H H 3-OH H H 4-41 H H Pn H H
3-OH H H 4-42 H Me Pn H H 3-OH H H 4-43 H Et Pn H H 3-OH H H 4-44
Me Me Pn H H 3-OH H H 4-45 Et Et Pn H H 3-OH H H 4-46 H H 3-MeBu H
H 3-OH H H 4-47 H Me 3-MeBu H H 3-OH H H 4-48 H Et 3-MeBu H H 3-OH
H H 4-49 Me Me 3-MeBu H H 3-OH H H 4-50 Et Et 3-MeBu H H 3-OH H H
4-51 H H Hx H H 3-OH H H 4-52 H Me Hx H H 3-OH H H 4-53 H Et Hx H H
3-OH H H 4-54 Me Me Hx H H 3-OH H H 4-55 Et Et Hx H H 3-OH H H 4-56
H H OH H H 3-OH H H 4-57 H Me OH H H 3-OH H H 4-58 H Et OH H H 3-OH
H H 4-59 Me Me OH H H 3-OH H H 4-60 Et Et OH H H 3-OH H H 4-61 H H
OMe H H 3-OH H H 4-62 H Me OMe H H 3-OH H H 4-63 H Et OMe H H 3-OH
H H 4-64 Me Me OMe H H 3-OH H H 4-65 Et Et OMe H H 3-OH H H 4-66 H
H OEt H H 3-OH H H 4-67 H Me OEt H H 3-OH H H 4-68 H Et OEt H H
3-OH H H 4-69 Me Me OEt H H 3-OH H H 4-70 Et Et OEt H H 3-OH H H
4-71 H H OPr H H 3-OH H H 4-72 H Me OPr H H 3-OH H H 4-73 H Et OPr
H H 3-OH H H 4-74 Me Me OPr H H 3-OH H H 4-75 Et Et OPr H H 3-OH H
H 4-76 H H OiPr H H 3-OH H H 4-77 H Me OiPr H H 3-OH H H 4-78 H Et
OiPr H H 3-OH H H 4-79 Me Me OiPr H H 3-OH H H 4-80 Et Et OiPr H H
3-OH H H 4-81 H H OBu H H 3-OH H H 4-82 H Me OBu H H 3-OH H H 4-83
H Et OBu H H 3-OH H H 4-84 Me Me OBu H H 3-OH H H 4-85 Et Et oBu H
H 3-OH H H 4-86 H H OiBu H H 3-OH H H 4-87 H Me OiBu H H 3-OH H H
4-88 H Et OiBu H H- 3-OH H H 4-89 Me Me OiBu H H 3-OH H H 4-90 Et
Et OiBu H H 3-OH H H 4-91 H H OsBu H H 3-OH H H 4-92 H Me OsBu H H
3-OH H H 4-93 H Et OsBu H H 3-OH H H 4-94 Me Me OsBu H H 3-OH H H
4-95 Et Et OsBu H H 3-OH H H 4-96 H H OtBu H H 3-OH H H 4-97 H Me
OtBu H H 3-OH H H 4-98 H Et OtBu H H 3-OH H H 4-99 Me Me OtBu H H
3-OH H H 4-100 Et Et OtBu H H 3-OH H H 4-101 H H OPn H H 3-OH H H
4-102 H Me OPn H H 3-OH H H 4-103 H Et OPn H H 3-OH H H 4-104 Me Me
OPn H H 3-OH H H 4-105 Et Et OPn H H 3-OH H H 4-106 H H O-3-MeBu H
H 3-OH H H 4-107 H Me O-3-MeBu H H 3-OH H H 4-108 H Et O-3-MeBu H H
3-OH H H 4-109 Me Me O-3-MeBu H H 3-OH H H 4-110 Et Et O-3-MeBu H H
3-OH H H 4-111 H H OHx H H 3-OH H H 4-112 H Me OHx H H 3-OH H H
4-113 H Et OHx H H 3-OH H H 4-114 Me Me OHx H H 3-OH H H 4-115 Et
Et OHx H H 3-OH H H 4-116 H H SH H H 3-OH H H 4-117 H Me SH H H
3-OH H H 4-118 H Et SH H H 3-OH H H 4-119 Me Me SH H H 3-OH H H
4-120 Et Et SH H H 3-OH H H 4-121 H H SMe H H 3-OH H H 4-122 H Me
SMe H H 3-OH H H 4-123 H Et SMe H H 3-OH H H 4-124 Me Me SMe H H
3-OH H H 4-125 Et Et SMe H H 3-OH H H 4-126 H H SEt H H 3-OH H H
4-127 H Me SEt H H 3-OH H H 4-128 H Et SEt H H 3-OH H H 4-129 Me Me
SEt H H 3-OH H H 4-130 Et Et SEt H H 3-OH H H 4-131 H H SPr H H
3-OH H H 4-132 H Me SPr H H 3-OH H H 4-133 H Et SPr H H 3-OH H H
4-134 Me Me SPr H H 3-OH H H 4-135 Et Et SPr H H 3-OH H H 4-136 H H
SiPr H H 3-OH H H 4-137 H Me SiPr H H 3-OH H H 4-138 H Et SiPr H H
3-OH H H 4-139 Me Me SiPr H H 3-OH H H 4-140 Et Et SiPr H H 3-OH H
H 4-141 H H SBu H H 3-OH H H 4-142 H Me SBu H H 3-OH H H 4-143 H Et
SBu H H 3-OH H H 4-144 Me Me SBu H H 3-OH H H 4-145 Et Et SBu H H
3-OH H H 4-146 H H SiBu H H 3-OH H H 4-147 H Me SiBu H H 3-OH H H
4-148 H Et SiBu H H 3-OH H H 4-149 Me Me SiBu H H 3-OH H H 4-150 Et
Et SiBu H H 3-OH H H 4-151 H H SsBu H H 3-OH H H 4-152 H Me SsBu H
H 3-OH H H 4 -153 H Et SsBu H H 3-OH H H 4-154 Me Me SsBu H H 3-OH
H H 4-155 Et Et SsBu H H 3-OH H H 4-156 H H StBu H H 3-OH H H 4-157
H Me StBu H H 3-OH H H 4-158 H Et StBu H H 3-OH H H 4-159 Me Me
StBu H H 3-OH H H 4-160 Et Et StBu H H 3-OH H H 4-161 H H SPn H H
3-OH H H 4-162 H Me SPn H H 3-OH H H 4-163 H Et SPn H H 3-OH H H
4-164 Me Me SPn H H 3-OH H H 4-165 Et Et SPn H H 3-OH H H 4-166 H H
S-3-MeBu H H 3-OH H H 4-167 H Me S-3-MeBu H H 3-OH H H 4-168 H Et
S-3-MeBu H H 3-OH H H 4-169 Me Me S-3-MeBu H H 3-OH H H 4-170 Et Et
S-3-MeBu H H 3-OH H H 4-171 H H SHx H H 3-OH H H 4-172 H Me SHx H H
3-OH H H 4-173 H Et SHx H H 3-OH H H 4-174 Me Me SHx H H 3-OH H H
4-175 Et Et SHx H H 3-OH H H 4-176 H H NH.sub.2 H H 3-OH H H 4-177
H Me NH.sub.2 H H 3-OH H H 4-178 H Et NH.sub.2 H H 3-OH H H 4-179
Me Me NH.sub.2 H H 3-OH H H 4-180 Et Et NH.sub.2 H H 3-OH H H 4-181
H H NHMe H H 3-OH H H 4-182 H Me NHMe H H 3-OH H H 4-183 H Et NHMe
H H 3-OH H H 4-184 Me Me NHMe H H 3-OH H H 4-185 Et Et NHMe H H
3-OH H H 4-186 H H NMe.sub.2 H H 3-OH H H 4-187 H Me NMe.sub.2 H H
3-OH H H 4-188 H Et NMe.sub.2 H H 3-OH H H 4-189 Me Me NMe.sub.2 H
H 3-OH H H 4-190 Et Et NMe.sub.2 H H 3-OH H H 4-191 H H NMeEt H H
3-OH H H 4-192 H Me NMeEt H H 3-OH H H 4-193 H Et NMeEt H H 3-OH H
H 4-194 Me Me NMeEt H H 3-OH H H 4-195 Et Et NMeEt H H 3-OH H H
4-196 H H NEt.sub.2 H H 3-OH H H 4-197 H Me NEt.sub.2 H H 3-OH H H
4-198 H Et NEt.sub.2 H H 3-OH H H 4-199 Me Me NEt.sub.2 H H 3-OH H
H 4-200 Et Et NEt.sub.2 H H 3-OH H H 4-201 H H NEtPr H H 3-OH H H
4-202 H Me NEtPr H H 3-OH H H 4-203 H Et NEtPr H H 3-OH H H 4-204
Me Me NEtPr H H 3-OH H H 4-205 Et Et NEtPr H H 3-OH H H 4-206 H H
NPr.sub.2 H H 3-OH H H 4-207 H Me NPr.sub.2 H H 3-OH H H 4-208 H Et
NPr.sub.2 H H 3-OH H H 4-209 Me Me NPr.sub.2 H H 3-OH H H 4-210 Et
Et NPr.sub.2 H H 3-OH H H 4-211 H H Me 4-Me 4-Me 3-OH H H 4-212 H H
Et 4-Me 4-Me 3-OH H H 4-213 H H Pr 4-Me 4-Me 3-OH H H 4-214 H H iPr
4-Me 4-Me 3-OH H H 4-215 H H Bu 4-Me 4-Me 3-OH H H 4-216 H H iBu
4-Me 4-Me 3-OH H H 4-217 H H sBu 4-Me 4-Me 3-OH H H 4-218 H H tBu
4-Me 4-Me 3-OH H H 4-219 H H Pn 4-Me 4-Me 3-OH H H 4-220 H H 3-MeBu
4-Me 4-Me 3-OH H H 4-221 H H Hx 4-Me 4-Me 3-OH H H 4-222 H H OH
4-Me 4-Me 3-OH H H 4-223 H H Me H H 3-OMe H H 4-224 H Me Me H H
3-OMe H H 4-225 H Et Me H H 3-OMe H H 4-226 Me Me Me H H 3-OMe H H
4-227 Et Et Me H H 3-OMe H H 4-228 H H OH H H 3-OMe H H 4-229 H Me
OH H H 3-OMe H H 4-230 H Et OH H H 3-OMe H H 4-231 Me Me OH H H
3-OMe H H 4-232 Et Et OH H H 3-OMe H H 4-233 H H Me H H 3-OEt H H
4-234 H Me Me H H 3-OEt H H 4-235 H Et Me H H 3-OEt H H 4-236 Me Me
Me H H 3-OEt H H 4-237 Et Et Me H H 3-OEt H H 4-238 H H OH H H
3-OEt H H 4-239 H Me OH H H 3-OEt H H 4-240 H Et OH H H 3-OEt H H
4-241 Me Me OH H H 3-OEt H H
4-242 Et Et OH H H 3-OEt H H 4-243 H H Me H H 3-OPr H H 4-244 H Me
Me H H 3-OPr H H 4-245 H Et Me H H 3-OPr H H 4-246 Me Me Me H H
3-OPr H H 4-247 Et Et Me H H 3-OPr H H 4-248 H H OH H H 3-OPr H H
4-249 H Me OH H H 3-OPr H H 4-250 H Et OH H H 3-OPr H H 4-251 Me Me
OH H H 3-OPr H H 4-252 Et Et OH H H 3-OPr H H 4-253 H H Me H H
3-OiPr H H 4-254 H Me Me H H 3-OiPr H H 4-255 H Et Me H H 3-OiPr H
H 4-256 Me Me Me H H 3-OiPr H H 4-257 Et Et Me H H 3-OiPr H H 4-258
H H OH H H 3-OiPr H H 4-259 H Me OH H H 3-OiPr H H 4-260 H Et OH H
H 3-OiPr H H 4-261 Me Me OH H H 3-OiPr H H 4-262 Et Et OH H H
3-OiPr H H 4-263 H H Me H H 3-SH H H 4-264 H Me Me H H 3-SH H H
4-265 H Et Me H H 3-SH H H 4-266 Me Me Me H H 3-SH H H 4-267 Et Et
Me H H 3-SH H H 4-268 H H OH H H 3-SH H H 4-269 H Me OH H H 3-SH H
H 4-270 H Et OH H H 3-SH H H 4-271 Me Me OH H H 3-SH H H 4-272 Et
Et OH H H 3-SH H H 4-273 H H Me H H 3-SMe H H 4-274 H Me Me H H
3-SMe H H 4-275 H Et Me H H 3-SMe H H 4-276 Me Me Me H H 3-SMe H H
4-277 Et Et Me H H 3-SMe H H 4-278 H H OH H H 3-SMe H H 4-279 H Me
OH H H 3-SMe H H 4-280 H Et OH H H 3-SMe H H 4-281 Me Me OH H H
3-SMe H H 4-282 Et Et OH H H 3-SMe H H 4-283 H H Me H H 3-SEt H H
4-284 H Me Me H H 3-SEt H H 4-285 H Et Me H H 3-SEt H H 4-286 Me Me
Me H H 3-SEt H H 4-287 Et Et Me H H 3-SEt H H 4-288 H H OH H H
3-SEt H H 4-289 H Me OH H H 3-SEt H H 4-290 H Et OH H H 3-SEt H H
4-291 Me Me OH H H 3-SEt H H 4-292 Et Et OH H H 3-SEt H H 4-293 H H
Me H H 3-SPr H H 4-294 H Me Me H H 3-SPr H H 4-295 H Et Me H H
3-SPr H H 4-296 Me Me Me H H 3-SPr H H 4-297 Et Et Me H H 3-SPr H H
4-298 H H OH H H 3-SPr H H 4-299 H Me OH H H 3-SPr H H 4-300 H Et
OH H H 3-SPr H H 4-301 Me Me OH H H 3-SPr H H 4-302 Et Et OH H H
3-SPr H H 4-303 H H Me H H 3-NH.sub.2 H H 4-304 H Me Me H H
3-NH.sub.2 H H 4-305 H Et Me H H 3-NH.sub.2 H H 4-306 Me Me Me H H
3-NH.sub.2 H H 4-307 Et Et Me H H 3-NH.sub.2 H H 4-308 H H OH H H
3-NH.sub.2 H H 4-309 H Me OH H H 3-NH.sub.2 H H 4-310 H Et OH H H
3-NH.sub.2 H H 4-311 Me Me OH H H 3-NH.sub.2 H H 4-312 Et Et OH H H
3-NH.sub.2 H H 4-313 H H Me H H 3-NHMe H H 4-314 H Me Me H H 3-NHMe
H H 4-315 H Et Me H H 3-NHMe H H 4-316 Me Me Me H H 3-NHMe H H
4-317 Et Et Me H H 3-NHMe H H 4-318 H H OH H H 3-NHMe H H 4-319 H
Me OH H H 3-NHMe H H 4-320 H Et OH H H 3-NHMe H H 4-321 Me Me OH H
H 3-NHMe H H 4-322 Et Et OH H H 3-NHMe H H 4-323 H H Me H H 3-NHEt
H H 4-324 H Me Me H H 3-NHEt H H 4-325 H Et Me H H 3-NHEt H H 4-326
Me Me Me H H 3-NHEt H H 4-327 Et Et Me H H 3-NHEt H H 4-328 H H OH
H H 3-NHEt H H 4-329 H Me OH H H 3-NHEt H H 4-330 H Et OH H H
3-NHEt H H 4-331 Me Me OH H H 3-NHEt H H 4-332 Et Et OH H H 3-NHEt
H H 4-333 H H Me H H 3-F H H 4-334 H Me Me H H 3-F H H 4-335 H Et
Me H H 3-F H H 4-336 Me Me Me H H 3-F H H 4-337 Et Et Me H H 3-F H
H 4-338 H H Et H H 3-F H H 4-339 H H Pr H H 3-F H H 4-340 H H iPr H
H 3-F H H 4-341 H H Bu H H 3-F H H 4-342 H H OH H H 3-F H H 4-343 H
H Me H H 3-Cl H H 4-344 H Me Me H H 3-Cl H H 4-345 H Et Me H H 3-Cl
H H 4-346 Me Me Me H H 3-Cl H H 4-347 Et Et Me H H 3-Cl H H 4-348 H
H Et H H 3-Cl H H 4-349 H H Pr H H 3-Cl H H 4-350 H H iPr H H 3-Cl
H H 4-351 H H Bu H H 3-Cl H H 4-352 H H OH H H 3-Cl H H 4-353 H H
NHEt H H 3-OH H H 4-354 H Me NHEt H H 3-OH H H 4-355 H Et NHEt H H
3-OH H H 4-356 Me Me NHEt H H 3-OH H H 4-357 Et Et NHEt H H 3-OH H
H 4-358 H H NHPr H H 3-OH H H 4-359 H Me NHPr H H 3-OH H H 4-360 H
Et NHPr H H 3-OH H H 4-361 Me Me NHPr H H 3-OH H H 4-362 Et Et NHPr
H H 3-OH H H
TABLE-US-00005 TABLE 5 (5) ##STR00011## Exemplified Compound Number
R.sup.1 R.sup.2 R.sup.10 R.sup.11 Z.sup.1 Z.sup.2 Z.sup.3 Z.sup.4
Z.sup.5 5-1 H H H H H H 3-OH H H 5-2 H H H Me H H 3-OH H H 5-3 H H
H Et H H 3-OH H H 5-4 H H Me Me H H 3-OH H H 5-5 H H Et Et H H 3-OH
H H 5-6 H H Pr Pr H H 3-OH H H 5-7 H H iPr iPr H H 3-OH H H 5- 8 H
H Bu Bu H H 3-OH H H 5-9 H H iBu iBu H H 3-OH H H 5-10 H H sBu sBu
H H 3-OH H H 5-11 H H tBu tBu H H 3-OH H H 5-12 H H OMe OMe H H
3-OH H H 5-13 H H OEt OEt H H 3-OH H H 5-14 H H OPr OPr H H 3-OH H
H 5-15 H H SMe SMe H H 3-OH H H 5-16 H H SEt SEt H H 3-OH H H 5-17
H H SPr SPr H H 3-OH H H 5-18 H H NH.sub.2 NH.sub.2 H H 3-OH H H
5-19 H H NHMe NHMe H H 3-OH H H 5-20 H H NHEt NEHEt H H 3-OH H H
5-21 H H NMe.sub.2 NMe.sub.2 H H 3-OH H H 5-22 H H NMeEt NMeEt H H
3-OH H H 5-23 H H NEt.sub.2 NEt.sub.2 H H 3-OH H H 5-24 H H H H
4-Me 4-Me 3-OH H H 5-25 H H H Me 4-Me 4-Me 3-OH H H 5-26 H H H Et
4-Me 4-Me 3-OH H H 5-27 H H Me Me 4-Me 4-Me 3-OH H H 5-28 H H Et Et
4-Me 4-Me 3-OH H H 5-29 H H Pr Pr 4-Me 4-Me 3-OH H H 5-30 H H iPr
iPr 4-Me 4-Me 3-OH H H 5-31 H H Bu Bu 4-Me 4-Me 3-OH H H 5-32 H H
iBu iBu 4-Me 4-Me 3-OH H H 5-33 H H sBu sBu 4-Me 4-Me 3-OH H H 5-34
H H tBu tBu 4-Me 4-Me 3-OH H H 5-35 H H H H 4-Et 4-Et 3-OH H H 5-36
H H H Me 4-Et 4-Et 3-OH H H 5-37 H H H Et 4-Et 4-Et 3-OH H H 5-38 H
H Me Me 4-Et 4-Et 3-OH H H 5-39 H H Et Et 4-Et 4-Et 3-OH H H 5-40 H
H Pr Pr 4-Et 4-Et 3-OH H H 5-41 H H iPr iPr 4-Et 4-Et 3-OH H H 5-42
H H Bu Bu 4-Et 4-Et 3-OH H H 5-43 H H iBu iBu 4-Et 4-Et 3-OH H H
5-44 H H sBu sBu 4-Et 4-Et 3-OH H H 5-45 H H tBu tBu 4-Et 4-Et 3-OH
H H 5-46 H H H H H H 3-OMe H H 5-47 H H H Me H H 3-OMe H H 5-48 H H
H H H H 3-OEt H H 5-49 H H H Me H H 3-OEt H H 5-50 H H H H H H
3-OPr H H 5-51 H H H Me H H 3-OPr H H 5-52 H H H H H H 3-OPr H H
5-53 H H H Me H H 3-OiPr H H 5-54 H H H H H H 3-SH H H 5-55 H H H
Me H H 3-SH H H 5-56 H H H H H H 3-SMe H H 5-57 H H H Me H H 3-SMe
H H 5-58 H H H H H H 3-SEt H H 5-59 H H H Me H H 3-SEt H H 5-60 H H
H H H H 3-SPr H H 5-61 H H H Me H H 3-SPr H H 5-62 H H H H H H
3-SiPr H H 5-63 H H H Me H H 3-SiPr H H 5-64 H H H H H H 3-NH.sub.2
H H 5-65 H H H Me H H 3-NH.sub.2 H H 5-66 H H SiPr SiPr H H 3-OH H
H
[0088] Amongst the above compounds, the preferred compounds are
Exemplified Compound Nos 1-1.about.1-27, 1-29.about.1-30, 1-32,
1-36.about.1-37, 1-40.about.1-41, 1-56, 1-58, 1-60, 1-62,
1-68.about.1-69, 1-71.about.1-72, 1-74.about.1-75,
1-86.about.1-109, 1-114.about.1-116, 1-120.about.1-122,
1-127.about.1-136, 1-147.about.1-153, 1-155.about.1-156,
1-158.about.1-165, 1-173.about.1-175, 1-178.about.1-183,
1-200.about.1-203, 2-1.about.2-3, 2-6.about.2-8, 2-11.about.2-13,
2-16.about.2-18, 2-21.about.2-23, 2-31.about.2-33, 2-36.about.2-38,
2-41.about.2-43, 2-46.about.2-48, 2-56.about.2-58, 2-61.about.2-63,
2-66.about.2-68, 2-71.about.2-73, 2-76.about.2-78, 2-81.about.2-83,
2-86.about.2-88, 2-91.about.2-93, 2-96.about.2-98,
2-101.about.2-109, [0089] 3-1.about.3-3, 3-6.about.3-8,
3-11.about.3-13, 3-16.about.3-18, 3-21.about.3-23, 3-26.about.3-32,
4-1.about.4-3, 4-6.about.4-8, 4-11.about.4-13, 4-16.about.4-18,
4-21.about.4-23, 4-26.about.4-28, 4-31.about.4-33, 4-36.about.4-38,
4-41.about.4-43, 4-46.about.4-48, 4-51.about.4-53, 4-56.about.4-58,
4-61.about.4-63, 4-66.about.4-68, 4-71.about.4-73, 4-76.about.4-78,
4-81.about.4-83, 4-85.about.4-88, 4-91.about.4-93, 4-96.about.4-98,
4-101.about.4-103, 4-106.about.4-108, 4-111.about.4-113,
4-116.about.4-118, 4-121.about.4-123, 4-126.about.4-128,
4-131.about.4-133, 4-136.about.4-138, 4-141.about.4-143,
4-146.about.4-148, 4-151.about.4-153, 4-156.about.4-158,
4-161.about.4-163, 4-166.about.4-168, 4-171.about.4-173,
4-176.about.4-178, 4-181.about.4-183, 4-186.about.4-188,
4-191.about.4-193, 4-196.about.4-198, 4-201.about.4-203,
4-206.about.4-208, 4-211.about.4-225, 4-228.about.4-230,
4-233.about.4-235, 4-238.about.4-240, 2-243.about.4-245,
4-248.about.4-250, 4-253.about.4-255, 4-258.about.4-260,
4-263.about.4-265, 4-268.about.4-270, 4-273.about.4-275,
4-278.about.4-280, 4-283.about.4-285, 4-288.about.4-290,
4-303.about.4-305, 4-308.about.4-310, 4-313.about.4-315,
4-318.about.4-320, 4-323.about.4-325, 4-328.about.4-330,
4-353.about.4-355, 4-358.about.4-360, [0090] 5-1.about.5-7,
5-12.about.5-17, 5-24.about.5-29, 5-35.about.5-40, 5-46.about.5-49,
5-54.about.5-57, 5-64.about.5-65 [0091] and the following are
further preferred: [0092] 1-1.about.1-6, 1-11.about.1-12,
1-20.about.1-26, 1-30, 1-71, 1-87, 1-89, 1-91.about.1-93,
1-100.about.1-106, 1-127.about.1-131, 1-147.about.1-150,
1-152.about.1-153, 1-155.about.1-156, 1-161, 1-173,
1-178.about.1-181, [0093] 2-1, 2-6, 2-11, 2-16, 2-21, 2-31, 2-36,
2-41, 2-46, 2-56, 2-61, 2-66, 2-71, 2-76, 2-81, 2-86, 2-91, 2-96,
2-102--2-107, 3-1, 3-6, 3-11, 3-16, 3-21, 3-26.about.3-28,
3-31.about.3-32, 4-1, 4-6, 4-11, 4-16, 4-21, 4-26, 4-31, 4-36,
4-41, 4-46, 4-51, 4-56, 4-61, 4-66, 4-71, 4-76, 4-81,
4-85.about.4-86, 4-91, 4-96, 4-101, 4-106, 4-111, 4-116, 4-121,
4-126, 4-131, 4-136, 4-141, 4-146, 4-151, 4-156, 4-201, 4-206,
4-211.about.4-222, 4-263, 4-303, 4-313, 4-353, 4-358,
5-1.about.5-6, 5-12.about.5-17, 5-24.about.5-29, 5-35.about.5-39,
5-54.about.5-55, 5-64.about.5-65 [0094] with the following being
still further preferred: [0095] 1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-22,
1-30, 1-71, 1-161, 1-173, 2-1, 2-11, 4-6, 4-11, 4-26, 4-31, 4-36,
4-81, 4-212 and 5-1 [0096] in particular, the following: [0097]
1-1: N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine [0098] 1-2:
2-methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine [0099]
1-3: 2-ethyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine [0100]
1-4: 2-propyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
[0101] 1-5:
2-isopropyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine [0102]
1-6: 2-butyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine [0103]
1-22: 2-amino-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
[0104] 1-173:
N,N'-bis(3-hydroxyphenyl)-5-nitropyrimidine-4,6-diamine [0105] 2-1:
N,N'-bis(3-hydroxyphenyl)pyrimidine-2,4-diamine [0106] 4-6:
6-ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine [0107]
4-11: N,N'-bis(3-hydroxyphenyl)-6-propyl-1,3,5-triazine-2,4-diamine
[0108] 4-26:
6-isobutyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
[0109] 4-31:
6-s-butyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
[0110] 4-36:
6-t-butyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
[0111] 4-212:
6-ethyl-N,N'-bis(3-hydroxy-4-methylphenyl)-1,3,5-triazine-2,4-diamine
and [0112] 5-1: N,N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine,
[0113] and most preferably [0114]
2-methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine and [0115]
N,N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine.
MODE OF PRACTISING THE INVENTION
[0116] The nitrogen-containing heteroaryl compounds represented by
general formulae (I) of the present invention and the
nitrogen-containing heteroaryl derivatives represented by general
formulae (VII) and (VIII) are either known compounds (for example
WO00/12485 pamphlet) or they can be produced by the following
method using known compounds as the starting materials.
##STR00012##
[0117] In the above formulae, R.sup.1, R.sup.2, Z.sup.1, Z.sup.2,
Z.sup.3, Z.sup.4, Z.sup.5 and A have the same meanings as above,
and X.sup.1 and X.sup.2 each represents a halogen atom (preferably
a chlorine atom, bromine atom or iodine atom, and more preferably a
chlorine atom).
[0118] Stage A-1 is a stage for the production of a compound of
general formula (XI) by the reaction between a halogen compound of
general formula (IX) and an aminophenol of general formula (X) in
an inert solvent.
[0119] The inert solvent used is not particularly restricted
providing it does not impede the reaction, and to some extent
dissolves the starting materials. Examples include aliphatic
hydrocarbons such as hexane, heptane, ligroin and petroleum ether;
aromatic hydrocarbons such as benzene, toluene and xylene;
halo-hydrocarbons such as dichloromethane, chloroform, carbon
tetrachloride, dichloroethane, chlorobenzene and dichlorobenzene;
nitriles such as acetonitrile and propionitrile; ethers such as
diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane,
dimethoxyethane and diethylene glycol dimethyl ether; amides such
as formamide, dimethylformamide, dimethylacetamide,
N-methyl-2-pyrrolidone and hexamethylphosphoramide; sulphoxides
such as dimethylsulphoxide and sulfolane; and alcohols such as
methanol, ethanol, propanol, 2-ethoxyethanol and 2-butoxyethanol.
The ethers, amides and alcohols are preferred, in particular
dioxane, diethylene glycol dimethyl ether, dimethylformamide,
dimethylacetamide, 2-ethoxyethanol or 2-butoxyethanol.
[0120] This stage can be carried out with the optional addition of
a base, such as an organic base like triethylamine,
N-methylmorpholine, pyridine, 4-(N,N-dimethylamino)-pyridine, or an
alkali metal carbonate such as sodium carbonate or potassium
carbonate. An organic base is preferred.
[0121] The reaction temperature will differ with the starting
material compounds and the solvent but, normally, it is
0-200.degree. C. and preferably 50-170.degree. C.
[0122] The reaction time will vary with the reaction temperature,
the starting material compounds and the solvent but, normally, it
is in the range from 10 minutes to 24 hours, and preferably 30
minutes to 8 hours.
[0123] Following the end of the reaction, the target material can
be obtained from the reaction mixture by the usual methods. For
example, following the end of the reaction the solvent is distilled
off and water poured onto the residue obtained, then extraction
performed with a water-immiscible solvent (such as benzene, ether,
ethyl acetate or the like), after which the extraction liquid is
washed with water and dried with anhydrous magnesium sulphate. By
then distilling off the solvent, the target compound is obtained.
The target compound thus obtained can, where necessary, be further
purified by the usual methods, such as column chromatography,
etc.
[0124] The aminophenol (X) used in stage A-1 is either a known
compound or can be readily produced by known methods [see J. Am.
Chem. Soc., Vol. 47, 1712-1718 (1925), J. Heterocyclic Chem., Vol.
26, 1255-1259 (1989), Synthesis, 1446-1450 (1997), J. Chem. Soc.,
3017-3020 (1949), J. Chem. Soc., 2426-2430 (1951)].
[0125] Stage A-2 is a stage for the production of the target
compound (I), and this is achieved by performing reaction between
the compound of general formula (XI) and an amine of general
formula (XII) in the same way as in stage A-1.
[0126] In the case where compound (X) and compound (XII) are the
same compound, then it is possible to obtain the desired compound
(I) by carrying out reaction in the same way as in stage A-1 using
at least 2 mol (preferably 2-3 mol) of compound (X) per mol of
halo-compound (IX).
[0127] The amine of general formula (XII) used in stage A-2 is
either a known compound or is readily produced by known methods
[Synth. Commun., Vol. 30, 3639-3644 (2000)].
[0128] The compound (IXa) where, in the compound of general formula
(IX) employed in stage A-1, A is a group of formula (V) and R.sup.9
is a C.sub.1-6 alkyl group, can be produced by the following method
B.
##STR00013##
[0129] In the above formulae, X.sup.1 and X.sup.2 have the same
meanings as above, and X.sup.3 represents a halogen atom
(preferably a chlorine atom, bromine atom or iodine atom, and more
preferably a chlorine atom), and R.sup.12 is a C.sub.1-6 alkyl
group.
[0130] Stage B-1 is a stage based on a known method [Helv. Chim.
Acta, Vol. 33, 1365-1369 (1950)] and is carried out by the reaction
between a trihalo-triazine compound of general formula (XIII) and
an alkali organo-metal (for example, an organo-lithium reagent such
as methyllithium, ethyllithium or propyllithium; an
organo-magnesium reagent such as methylmagnesium bromide or
ethyl-magnesium bromide; an organo-aluminium reagent such as
trimethylaluminium; an organo-zinc reagent such as dimethylzinc; or
an organo-copper reagent such as lithium dimethyl-cuprate;
preferably an organo-lithium reagent or an organo-magnesium
reagent) in an inert solvent (for example an aliphatic hydrocarbon
such as hexane; an aromatic hydrocarbon such as benzene or toluene;
a halo-hydrocarbon such as dichloromethane; or an ether such as
diethyl ether or diethylene glycol dimethyl ether; preferably an
aromatic hydrocarbon or an ether, and in particular benzene,
toluene, tetrahydrofuran or diethyl ether), at -78.degree. C. to
50.degree. C. (preferably -30.degree. C. to 30.degree. C.) for from
10 minutes to 8 hours (preferably 30 minutes to 3 hours).
[0131] After the completion of the reaction, the target compound is
obtained from the reaction mixture by the usual methods. For
example, the reaction mixture is concentrated or extracted with a
water-immiscible organic solvent (such as benzene, ether, ethyl
acetate or the like), followed by drying with anhydrous magnesium
sulphate, after which the solvent is distilled off. Where required,
the target material thus obtained can be further purified by normal
methods, for example by column chromatography.
[0132] The compound of general formula (IX) used in stage A-1 can
also be produced by the following method C.
##STR00014##
[0133] In the above formulae, X.sup.1, X.sup.2 and A have the same
meanings as above.
[0134] Stage C-1 is a stage based on a known method [J. Org. Chem.,
Vol. 17, 1320-1327 (1952); J. Org. Chem., Vol. 18, 653-656 (1953);
J. Am. Chem. Soc. Vol. 79, 2230-2232 (1957)] by the reaction
between a compound of general formula (XIV) and a halogenating
agent (such as a thionyl halide such as thionyl chloride; a
phosphorus trihalide such as phosphorus trichloride, phosphorus
tribromide or phosphorus triiodide; a phosphorus pentahalide such
as phosphorus pentachloride, phosphorus pentabromide or phosphorus
pentaiodide; or a phosphorus oxyhalide such as phosphorus
oxychloride, phosphorus oxybromide or phosphorus oxyiodide; in
particular with phosphorus oxychloride) either in the absence of
solvent or in the presence of an inert solvent (such as an
aliphatic hydrocarbon such as hexane or heptane; an aromatic
hydrocarbon such as benzene or toluene; a halo-hydrocarbon such as
dichloroethane or dichlorobenzene; an ether such as diethyl ether
or diethylene glycol dimethyl ether; or an organic base such as
N-methylmorpholine, triethylamine, N-methyl-piperidine, pyridine,
quinoline or dimethylaniline; preferably in an organic base or in
the absence of solvent, and in particular in dimethylaniline), at
20-180.degree. C. (preferably 70-150.degree. C.) for from 1 hour to
24 hours (preferably 3 to 5 hours). In the case where no solvent is
employed, the reaction is carried out using excess of the
halogenating agent.
[0135] Following the end of the reaction, the target compound is
obtained from the reaction mixture by the usual methods. For
example, the reaction mixture is concentrated or extracted with a
water-immiscible organic solvent (such as benzene, ether, ethyl
acetate or the like), followed by drying with anhydrous magnesium
sulphate, after which the solvent is distilled off and the target
material obtained. Where required, the target material thus
obtained can be further purified by normal methods, for example by
column chromatography.
[0136] In the case where the nitrogen-containing heteroaryl
compounds of general formula (I) of the present invention, or
pharmacologically permitted salts thereof, are used as preventives
or remedies for Alzheimer's disease or as amyloid protein
fibril-formation inhibitors, they can be administered orally in the
form of tablets, capsules, granules, powders or syrups, etc, or
parenterally in the form of injections or suppositories, etc,
either on their own or after mixing with suitable
pharmacologically-permitted fillers, diluents or the like.
[0137] These pharmaceutical preparations are produced by known
methods using additives such as fillers/excipients (examples of
which are organic fillers like lactose, sucrose, glucose, mannitol,
sorbitol or other sugar or sugar derivative; corn starch, potato
starch, .alpha.-starch, dextrin or other such starch or starch
derivative; crystalline cellulose or other such cellulose
derivative; gum Arabic; dextran; pullulan or the like; and
inorganic fillers like light silica, synthetic aluminium silicate;
calcium silicate, magnesium metasilicate or other silicic acid
derivative; calcium hydrogen phosphate or other phosphate; calcium
carbonate or other carbonate; calcium sulphate or other sulphate,
or the like), lubricants (examples of which are stearic acid and
metal stearates like calcium stearate and magnesium stearate; talc;
colloidal silica; beeswax, sperm whale wax and other such waxes;
boric acid; adipic acid; sulphates such as sodium sulphate; glycol;
fumaric acid; sodium benzoate; DL-leucine; sodium laurylsulphate,
magnesium laurylsulphate and other such laurylsulphates; silicic
anhydride, silicic acid hydrate and other silicas; and also the
aforesaid starch derivatives), binders (examples of which are
hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl
pyrrolidone, macrogol and compounds identical to the aforesaid
fillers), disintegrating agents (cellulose derivatives such as
hydroxypropyl cellulose with a low degree of substitution,
carboxymethyl cellulose, calcium carboxymethyl cellulose and
internally-crosslinked sodium carboxymethyl cellulose;
carboxymethyl starch, sodium, carboxymethyl starch, crosslinked
polyvinyl pyrrolidone and other such chemically-modified
starch/cellulose or the like), emulsifiers (for example bentonite,
veegum and other types of colloidal clay; magnesium hydroxide,
aluminium hydroxide and other such metal hydroxides; sodium lauryl
sulphate, calcium stearate and other such anionic surfactants;
benzalkonium chloride and other types of cationic surfactants; and
polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid
ester, sucrose fatty acid ester and other such nonionic
surfactants), stabilizers (methyl paraben, propyl paraben and other
such p-hydroxybenzoic acid esters; chlorobutanol, benzyl alcohol,
phenyl ethyl alcohol and other such alcohols; benzalkonium
chloride; phenol, cresol and other such phenols; thimerosal;
dehydroacetic acid; and sorbic acid), correctives/corrigents (such
as the normally used sweeteners, acidic taste-conferrers, spices
and the like), diluents and other such additives.
[0138] The amount used will differ according to the symptoms, age,
etc, but when administered orally to an adult there can be used an
amount between a lower limit of 1 mg (preferably 10 mg) and an
upper limit of 1,000 mg (preferably 500 mg) per time, and when
administered intravenously there can be used an amount between a
lower limit of 0.5 mg (preferably 5 mg) and an upper limit of 500
mg (preferably 250 mg) per time, from once to six times per day
according to the symptoms.
OPTIMUM MODE FOR PRACTISING THE INVENTION
[0139] Below, the present invention is explained in still further
detail by providing some production examples, experimental and
preparation examples, but the invention is not to be restricted to
these.
PRODUCTION EXAMPLE 1
6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-6)
(1A) 2,4-dichloro-6-ethyl-1,3,5-triazine
[0140] This compound was prepared based on a known method [Helv.
Chem. Acta, 33, 1365-1369 (1950)]. That is to say,
2,4,6-trichloro-1,3,5-triazine (4.61 g, 25.0 mmol) was dissolved in
benzene (50.0 mL) under an atmosphere of nitrogen and the solution
cooled with an ice bath.
[0141] While stirring the solution, ethylmagnesium bromide (3.0 M
ether solution, 10.0 mL) was slowly added over 20 minutes and
stirring carried out for a further 30 minutes while ice cooling.
The reaction was monitored by thin layer chromatography and,
following the end of the reaction, saturated aqueous ammonium
chloride solution (20.0 mL) was added to the reaction liquid and
stirring carried out. Ether (200 mL) was also added and liquid
separation performed. The organic layer obtained was removed,
washed with distilled water (20.0 mL) and then with saturated
sodium chloride solution (20.0 mL), after which drying was carried
out with anhydrous magnesium sulphate. By distilling off the
solvent under reduced pressure, the crude target compound was
obtained.
[0142] The crude compound thus obtained was purified using silica
gel chromatography (elution solvent: hexane/ethyl acetate=100/1,
v/v) and the target compound obtained (2.67 g, 60% yield).
(1B)
6-ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
[0143] After dissolving 3-aminophenol (2.18 g, 20 mmol) in
1,4-dioxane (20.0 mL), 2,4-dichloro-6-ethyl-1,3,5-triazine (1.78 g,
10 mmol) was added and stirring carried out for 3 hours at
100.degree. C. under a nitrogen atmosphere.
[0144] Following the end of the reaction, the solvent was distilled
off under reduced pressure and the residue purified using silica
gel column chromatography (elution solvent: methylene
chloride/methanol=20/1, v/v) and the target compound obtained (2.26
g, yield 70%).
[0145] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 1.29(3H, t,
J=7.6 Hz), 2.68(2H, q, J=7.6 Hz), 6.59(2H, d, J=7.2 Hz), 7.04(2H,
brs), 7.13(2H, t, J=8.0 Hz), 7.18(2H, d, J=7.2 Hz).
[0146] Mass spectrum (EI), m/z: 323 (M.sup.+)
PRODUCTION EXAMPLE 2
2-Ethyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-3)
(2A) 4,6-dichloro-2-ethylpyrimidine
[0147] Preparation was carried out based on a known method [J.
Org., Vol. 18, 653-656 (1953)]. That is to say, an excess amount of
phosphoryl chloride (6.34 mL, 70.0 mmol) was added to
2-ethyl-1H-pyrimidine-4,6-dione (1.40 g, 10.0 mmol) and the
reaction mixture heated under reflux for 2 hours. After the solid
material had completely dissolved, the reaction mixture was cooled
to room temperature, and the unreacted phosphoryl chloride
distilled off under reduced pressure. The residue was added to
finely crushed ice (200 g) and left. After the ice had melted,
ether (200 mL) was added to the reaction mixture, and liquid
separation performed. The organic layer obtained was removed,
washed with distilled water (20.0 mL) and then with saturated
aqueous sodium chloride solution (20.0 mL), after which drying was
performed with anhydrous magnesium sulphate. By distilling off the
solvent under reduced pressure, crude target compound was obtained
(1.68 g, crude yield 95%).
[0148] The crude compound obtained was used in the next reaction
without further purification.
(2B) 2-ethyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
[0149] After dissolving 3-aminophenol (1.09 g, 10.0 mmol) in
2-ethoxyethanol (5.0 mL), 4,6-dichloro-2-ethylpyrimidine (0.89 g,
5.0 mmol) was added and stirring carried out for 5 hours at
130.degree. C.
[0150] The reaction was monitored by thin layer chromatography and,
following the end of the reaction, the solvent was distilled off
under reduced pressure. The residue was purified using silica gel
column chromatography (elution solvent: methylene
chloride/methanol=20/1, v/v) and the target compound obtained (0.97
g, yield 60%).
[0151] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 1.27(3H, t,
J=7.4 Hz), 2.62(2H, q, J=7.4 Hz), 6.06(1H, s), 6.37(2H, m),
6.96(2H, m), 7.01-7.09(4H, m), 8.91(2H, brs), 9.27(2H, m).
[0152] Mass spectrum (EI), m/z: 322 (M.sup.+)
PRODUCTION EXAMPLE 3
2-Methyl-N-(3-hydroxyphenyl)-N'-(3-methoxyphenyl)-pyrimidine-4,6-diamine
(Exemplified Compound No. 1-108)
(3A) 2-methyl-4-chloro-6-(3-hydroxyphenylamino)-pyrimidine
[0153] 4,6-dichloro-2-methylpyrimidine (1.63 g, 10.0 mmol) prepared
based on the method described in Production Example 2A above using
2-methyl-1H-pyrimidine-4,6-dione instead of the
2-ethyl-1H-pyrimidine-4,6-dione, was slowly added to a
2-ethoxyethanol (5.0 mL) solution of 3-aminophenol (1.09 g, 10.0
mmol) and the reaction mixture heated for 4 hours at 130.degree. C.
The reaction was monitored by thin layer chromatography and,
following the end of the reaction, the reaction mixture was cooled
to room temperature and the precipitated white powder filtered off.
The crude product filtered off was used in the subsequent reaction
without further purification (1.76 g, crude yield 75%).
[0154] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 2.42(3H, s),
6.50(1H, m), 6.73(1H, s), 7.05(1H, m), 7.12(1H, m), 7.19(1H, s),
10.00(1H, s).
[0155] Mass spectrum (EI), m/z: 234 (M-H.sup.+)
(3B)
2-methyl-N-(3-hydroxyphenyl)-N'-(3-methoxyphenyl)-pyrimidine-4,6-diam-
ine
[0156] 2-methyl-4-chloro-6-(3-hydroxyphenylamino)pyrimidine (0.71
g, 3.0 mmol) was added to a 2-ethoxyethanol (2.0 mL) solution of
3-methoxyaniline (0.37 g, 3.0 mmol) under a nitrogen atmosphere and
the reaction mixture stirred for 5 hours at 130.degree. C.
[0157] The reaction was monitored by thin layer chromatography and,
at the end of the reaction, the solvent was distilled off under
reduced pressure. The residue was purified using silica gel column
chromatography (elution solvent: methylene chloride/methanol=20/1,
v/v) and the target compound obtained (0.48 g, yield 50%)
[0158] .sup.1H NMR spectrum (CDCl.sub.3, 400 MHz), .delta.:
2.40(3H, s), 3.75(3H, s), 6.16(1H, s), 6.59-6.74(4H, m), 6.75(1H,
t, J=2.2 Hz), 6.83(1H, t, J=2.2 Hz), 6.95(2H, brs), 7.13(1H, t,
J=8.0 Hz), 7.18(1H, t, J=8.0 Hz).
[0159] Mass spectrum (EI), m/z: 322 (M.sup.+)
PRODUCTION EXAMPLE 4
2-Methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-2)
[0160] This compound was obtained (yield 60%) based on the method
described in Production Example 2B using
4,6-dichloro-2-methylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0161] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 2.35(3H, s),
6.05(1H, s), 6.35(2H, m), 6.92(2H, m), 7.00-7.10(4H, m), 8.95(1H,
brs), 9.30(1H, s).
[0162] Mass spectrum (EI), m/z: 308 (M.sup.+)
PRODUCTION EXAMPLE 5
N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine (Exemplified
Compound No. 1-1)
[0163] This compound was obtained (yield 60%) based on the method
described Inc Production Example 2B using 4,6-dichloropyrimidine
instead of the 4,6-dichloro-2-ethylpyrimidine.
[0164] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 6.20(1H, s),
6.38(2H, m), 6.92(2H, m), 7.01-7.13(4H, m), 8.25(1H, s), 9.02(1H,
s), 9.31(1H, s).
[0165] Mass spectrum (EI), m/z: 294 (M.sup.+)
PRODUCTION EXAMPLE 6
N,N'-bis(3-hydroxyphenyl)pyrimidine-2,4-diamine (Exemplified
Compound No. 2-1)
[0166] This compound was obtained (yield 80%) based on the method
described in Production Example 2B using 2,4-dichloropyrimidine
instead of the 4,6-dichloro-2-ethylpyrimidine.
[0167] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 6.46(2H, d,
J=8.6 Hz), 6.63(2H, m), 6.85(1H, s), 6.95-7.06(2H, m),
7.10-7.30(3H, m), 7.93(1H, d, J=8.2 Hz), 9.62(1H, brs), 10.47(1H,
s), 10.80(1H, s).
[0168] Mass spectrum (EI), m/z: 294 (M.sup.+)
PRODUCTION EXAMPLE 7
5,6-Dimethyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-2,4-diamine
(Exemplified Compound No. 2-11)
[0169] This compound was obtained (yield 78%) based on the method
described in Production Example 2B using
2,4-dichloro-5,6-dimethylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0170] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 2.12(3H, s),
2.37(3H, s), 6.49(1H, dd, J=1.6, 8.2 Hz), 6.67(2H, m), 6.88(1H, t,
J=1.6 Hz), 6.94-7.20(2H, m), 7.06(1H, d, J=8.2 Hz), 7.18(1H, t,
J=8.2 Hz), 9.40-9.60(4H, brs).
[0171] Mass spectrum (EI), m/z: 322 (M.sup.+)
PRODUCTION EXAMPLE 8
2-Butyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-6)
[0172] This compound was obtained (yield 73%) based on the method
described in Production Example 2B using
4,6-dichloro-2-butylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0173] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 0.94(3H, t,
J=7.5 Hz), 1.38(2H, sextet, J=7.5 Hz), 1.76(2H, quintet, J=7.5 Hz),
2.64(2H, t, J=7.5 Hz), 6.08(1H, s), 6.44(1H, dd, J=1.6, 8.0 Hz),
6.95(2H, d, J=8.0 Hz), 7.00(2H, m), 7.08(2H, t, J=8.0 Hz), 9.17(2H,
s), 9.40(2H, s).
[0174] Mass spectrum (EI), m/z: 350 (M.sup.+)
PRODUCTION EXAMPLE 9
2-Propyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound 1-4)
[0175] This compound was obtained (yield 68%) based on the method
described in Production Example 2B using
4,6-dichloro-2-propylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0176] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 0.96(3H, t,
J=7.2 Hz), 1.79(2H, sextet, J=7.2 Hz), 2.58(2H, t, J=7.2 Hz),
6.06(1H, s), 6.37(2H, dd, J=1.2, 7.6 Hz), 6.96(2H, d, J=8.8 Hz),
7.02-7.07(4H, m), 8.90(2H, s), 9.28(2H, s).
[0177] Mass spectrum (EI), m/z: 336 (M.sup.+)
PRODUCTION EXAMPLE 10
N,N'-bis(3-hydroxyphenyl)-6-propyl-1,3,5-triazine-2,4-diamine
(Exemplified Compound 4-11)
[0178] This compound was obtained (yield 62%) based on the method
described in Production Example 1B using
2,4-dichloro-6-propyl-1,3,5-triazine instead of the
2,4-dichloro-6-ethyl-1,3,5-triazine.
[0179] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 0.96(3H, t,
J=7.2 Hz), 1.77(2H, sextet, J=7.2 Hz), 2.51(2H, t, J=7.2 Hz),
6.42(2H, dd, J=2.0, 8.0 Hz), 7.05(2H, t, J=8.0 Hz), 7.14(2H, brs),
7.31(2H, d, J=8.0 Hz), 9.26(2H, brs), 9.51(2H, brs).
[0180] Mass spectrum (EI), m/z: 337 (M.sup.+)
PRODUCTION EXAMPLE 11
N-ethyl-N,N'-bis(3-hydroxyphenyl)-2-methylpyrimidine-4,6-diamine
(Exemplified Compound No. 1-30)
[0181] This compound was obtained (yield 45%) based on the method
described in Production Example 3B using 3-ethylaminophenol instead
of the 3-methoxyaniline.
[0182] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 1.06(3H, t,
J=7.3 Hz), 2.32(3H, s), 3.87(2H, q, J=7.3 Hz), 5.39(1H, s),
6.25(1H, dd, J=2.2, 8.0 Hz), 6.61(1H, m), 6.66(1H, d, J=8.0 Hz),
6.71(1H, dd, J=2.2, 8.0 Hz), 6.86(1H, d, J=8.0 Hz), 6.92(1H, t,
J=8.0 Hz), 7.05(1H, m), 7.25(1H, t, J=8.0 Hz), 8.28(1H, s),
8.68(1H, s), 9.17(1H, brs), 9.65(2H, brs).
[0183] Mass spectrum (EI), m/z: 336 (M.sup.+)
PRODUCTION EXAMPLE 12
N,N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine (Exemplified
Compound 5-1)
[0184] This compound was obtained (yield 55%) based on the method
described in Production Example 2B using 3,6-dichloropyridazine
instead of the 4,6-dichloro-2-ethylpyrimidine.
[0185] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 6.28(2H, dd,
J=2.2, 7.7 Hz), 6.96-7.07(4H, m), 7.06(2H, s), 7.44(2H, t, J=2.2
Hz), 8.78(1H, s), 9.23(1H, s).
[0186] Mass spectrum (EI), m/z: 294 (M.sup.+)
PRODUCTION EXAMPLE 13
2-Amino-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-22)
[0187] This compound was obtained (yield 55%) based on the method
described in Production Example 2B using
2-amino-4,6-dichloropyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0188] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 5.49(1H, s),
6.35(2H, d, J=8.0 Hz), 6.75(2H, brs), 6.77-6.86(4H, m), 6.96(2H, t,
J=8.0 Hz), 9.14(2H, brs), 9.36(2H, brs).
[0189] Mass spectrum (FAB), m/z: 310 (M+H.sup.+)
PRODUCTION EXAMPLE 14
2-Methylthio-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-20)
[0190] This compound was obtained (yield 62%) based on the method
described in Production Example 2B using
4,6-dichloro-2-methylthio-pyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0191] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 2.48(3H, s),
5.91(1H, s), 6.39(2H, dd, J=1.4, 8.0 Hz), 6.92(2H, d, J=8.0 Hz),
6.99(2H, m), 7.06(2H, t, J=8.0 Hz), 9.01(2H, s), 9.31(2H, s).
[0192] Mass spectrum (EI), m/z: 340 (M.sup.+)
PRODUCTION EXAMPLE 15
2-Methylthio-N,N'-diethyl-N,N'-bis(3-hydroxyphenyl)-pyrimidine-4,6-diamine
(Exemplified Compound No. 1-71)
[0193] This compound was obtained (yield 43%) based on the method
described in Production Example 2B using
4,6-dichloro-2-methylthio-pyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine, and using 3-ethylaminophenol
instead of the 3-aminophenol.
[0194] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 1.04(6H, t,
J=7.3 Hz), 2.42(3H, s), 3.80(4H, q, J=7.3 Hz), 4.87(1H, s),
6.50-6.60(6H, m), 7.09(2H, t, J=8.0 Hz), 9.42(2H, brs).
[0195] Mass spectrum (EI), m/z: 396 (M.sup.+)
PRODUCTION EXAMPLE 16
6-Butoxy-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-81)
[0196] This compound was obtained (yield 62%) based on the method
described in Production. Example 1B using
6-butoxy-2,4-dichloro-1,3,5-triazine (10.0 mmol) instead of the
2,4-dichloro-6-ethyl-1,3,5-triazine.
[0197] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 0.94(3H, t,
J=7.2 Hz), 1.42(2H, sextet, J=7.2 Hz), 1.70(2H, quintet, J=7.2 Hz),
4.31(2H, t, J=7.2 Hz), 6.43(2H, dd, J=2.0, 8.0 Hz), 7.05(2H, t,
J=8.0 Hz), 7.14(2H, brs), 7.25(2H, brs), 9.28(2H, brs), 9.45(2H,
brs).
[0198] Mass spectrum (FAB), m/z: 368 (M+H.sup.+)
PRODUCTION EXAMPLE 17
6-Butoxy-N,N'-diethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-85)
[0199] This compound was obtained (yield 47%) based on the method
described in Production Example 1B using
6-butoxy-2,4-dichloro-1,3,5-triazine instead of the
2,4-dichloro-6-ethyl-1,3,5-triazine, and using 3-ethylaminophenol
instead of the 3-aminophenol.
[0200] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 0.83(3H, t,
J=7.3 Hz), 1.08(6H, m), 1.24(2H, m), 1.52(2H, m), 3.79(4H, m),
4.02(2H, m), 6.60-6.70(6H, m), 7.15(2H, t, J=8.0 Hz).
[0201] Mass spectrum (FAB), m/z: 424 (M+H.sup.+)
PRODUCTION EXAMPLE 18
N,N'-bis(3-hydroxyphenyl)-5-nitropyrimidine-4,6-diamine
(Exemplified Compound No. 1-173)
[0202] This compound was obtained (yield 80%) based on the method
described in Production Example 2B using
4,6-dichloro-5-nitropyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0203] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 6.65(2H, m),
7.95(2H, m), 7.10-7.22(4H, m), 8.20(1H, s), 9.60(2H, m), 10.80(2H,
brs).
[0204] Mass spectrum (EI), m/z: 339 (M.sup.+)
PRODUCTION EXAMPLE 19
N,N'-bis(3-hydroxy-2-methylphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-86)
[0205] This compound was obtained (yield 40%) based on the method
described in Production Example 2B using 4,6-dichloropyrimidine
instead of the 4,6-dichloro-2-ethylpyrimidine, and using
3-amino-2-methylphenol instead of the 3-aminophenol.
[0206] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 1.95(6H, s),
5.48(1H, s), 6.61(2H, d, J=5.3 Hz), 6.73(2H, d, J=5.3 Hz), 6.92(2H,
d, J=5.3 Hz), 8.00(1H, s), 8.29(1H, s), 9.30(1H, brs).
[0207] Mass spectrum (EI), m/z: 322 (M.sup.+)
PRODUCTION EXAMPLE 20
N,N'-(3-hydroxy-2-methylphenyl)pyrimidine-2,4-diamine (Exemplified
Compound No. 2-101)
[0208] This compound was obtained (yield 50%) based on the method
described in Production Example 2B using 2,4-dichloropyrimidine
(0.74 g, 5.00 mmol) instead of the 4,6-dichloro-2-ethylpyrimidine,
and using 3-amino-2-methylphenol instead of the 3-aminophenol.
[0209] Mass spectrum (EI), m/z: 322 (M.sup.+)
PRODUCTION EXAMPLE 21
N,N'-bis(3-hydroxy-4-methoxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-88)
[0210] This compound was obtained (yield 67%) based on the method
described in Production Example 2B using 4,6-dichloropyrimidine
instead of the 4,6-dichloro-2-ethylpyrimidine, and using
3-amino-4-methoxyphenol instead of the 3-aminophenol.
[0211] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 3.73(6H, s),
5.93(1H, s), 6.81(4H, m), 7.00(2H, s), 8.12(1H, s), 8.71(1H, brs),
8.99(1H, brs).
[0212] Mass spectrum (EI), m/z: 354 (M.sup.+)
PRODUCTION EXAMPLE 22
6-Methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-2,4-diamine
(Exemplified Compound 2-6)
[0213] This compound was obtained (yield 71%) based on the method
described in Production Example 2B using
2,4-dichloro-6-methylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0214] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 2.36(3H, s),
6.17(1H, s), 6.46(1H, dd, J=1.9, 8.5 Hz), 6.50(1H, dd, J=1.9, 8.5
Hz), 6.94(1H, s), 7.01-7.12(3H, m), 7.20(2H, t, J=8.5 Hz), 9.35(1H,
s), 9.44(1H, s), 9.50(1H, brs), 9.80(1H, brs).
[0215] Mass spectrum (EI), m/z: 308 (M.sup.+)
PRODUCTION EXAMPLE 23
2-Methyl-N-(3-chlorophenyl)-N'-(3-hydroxyphenyl)-pyrimidine-4,6-diamine
(Exemplified Compound 1-161)
[0216] This compound was obtained (yield 57%) based on the method
described in Production Example 3B using 3-chloroaniline instead of
the 3-methoxyaniline.
[0217] .sup.1H NMR spectrum (CDCl.sub.3, 400 MHz), .delta.:
3.49(3H, s), 6.10(1H, s), 6.62(1H, dd, J=2.0, 7.6 Hz),
6.73-6.78(3H, m), 7.04-7.11(2H, m), 7.17-7.25(2H, m), 7.33(1H, t,
J=2.0 Hz).
[0218] Mass spectrum (EI), m/z: 326 (M.sup.+)
PRODUCTION EXAMPLE 24
2-Methyl-N,N'-bis(4,6-difluoro-3-hydroxyphenyl)-pyrimidine-4,6-diamine
(Exemplified Compound No. 1-171)
[0219] This compound was obtained (yield 57%) based on the method
described in Production Example 2B using
4,6-dichloro-2-methylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine, and using
5-amino-2,4-difluorophenol instead of the 3-aminophenol.
[0220] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 2.30(3H, s),
5.77(1H, s), 7.21(2H, t, .sup.8J.sub.HF=11.0 Hz), 7.41(2H, t,
.sup.4J.sub.RF=8.8 Hz), 8.58(2H, brs), 9.79(2H, brs).
[0221] Mass spectrum (EI), m/z: 380 (M.sup.+)
PRODUCTION EXAMPLE 25
2-Isopropyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-5)
[0222] This compound was obtained. (yield 65%) based on the method
described in Production Example 2B using
4,6-dichloro-2-isopropylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine.
[0223] .sup.1H NMR spectrum (CD.sub.3OD, 400 MHz), .delta.:
1.32(6H, d, J=6. 9 Hz), 2.88(1H, septet, J=6.9 Hz), 6.08(1H, s),
6.47(2H, ddd, J=0.9, 2.2, 8.1 Hz), 6.90(2H, ddd, J=0.9, 2.2, 8.1
Hz), 6.98(2H, t, J=2.2 Hz), 7.09(2H, t, J=8. 1 Hz).
[0224] Mass spectrum (EI), m/z: 336 (M.sup.+)
PRODUCTION EXAMPLE 26
2-Methyl-N,N'-bis(3-hydroxy-5-trifluoromethylphenyl)-pyrimidine-4,6-diamin-
e (Exemplified Compound No. 1-90)
[0225] This compound was obtained (yield 43%) based on the method
described in Production Example 2B using
4,6-dichloro-2-methylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine, and using
3-amino-5-trifluoromethylphenol instead of the 3-aminophenol.
[0226] .sup.1H NMR spectrum (CD.sub.3OD, 400 MHz), .delta.:
2.46(3H, s), 6.05(1H, s), 6.68(2H, m), 7.30(2H, m), 7.34(2H, t,
J=2.0 Hz).
[0227] Mass spectrum (EI), m/z: 444 (M.sup.+)
PRODUCTION EXAMPLE 27
N,N'-bis(3-hydroxyphenyl)-6-methyl-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-1)
[0228] This compound was obtained (yield 73%) based on the method
described in Production Example 1B using
2,4-dichloro-6-methyl-1,3,5-triazine instead of the
2,4-dichloro-6-ethyl-1,3,5-triazine.
[0229] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 2.29(3H, s),
6.43(2H, dd, J=2.4, 8.0 Hz) 7.06(2H, t, J=8.0 Hz), 7.13(2H, brs),
7.30(2H, d, J=8.0 Hz), 9.27(2H, brs), 9.53(2H, brs).
[0230] Mass spectrum (EI), m/z: 309 (M.sup.+)
PRODUCTION EXAMPLE 28
6-Butyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-21)
[0231] This compound was obtained (yield 68%) based on the method
described in Production Example 1B using
6-butyl-2,4-dichloro-1,3,5-triazine instead of the
2,4-dichloro-6-ethyl-1,3,5-triazine.
[0232] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 0.92(3H, t,
J=7.3 Hz), 1.37(2H, sextet, J=7/3 Hz), 1.73(2H, quintet, J=8.0 Hz),
2.51(2H, m), 6.42(2H, dd, J=2.5, 8.0 Hz), 7.05(2H, t, J=8.0 Hz),
7.13(2H, s), 7.31(2H, d, J=8.0 Hz), 9.26(2H, brs), 9.51(2H,
brs).
[0233] Mass spectrum (EI) m/z: 351 (M.sup.+)
PRODUCTION EXAMPLE 29
N,N'-dimethyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine
(Exemplified Compound No. 1-28)
[0234] This compound was obtained (yield 43%) based on the method
described in Production Example 2B using 4,6-dichloropyrimidine
instead of the 4,6-dichloro-2-ethylpyrimidine, and using
3-methylaminophenol instead of the 3-aminophenol.
[0235] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 3.28(6H, s),
5.50(1H, s), 6.54-6.64(6H, m), 7.11(2H, t, J=8.0 Hz), 8.21(1H, s),
9.50(2H, brs).
[0236] Mass spectrum (EI), m/z: 340 (M.sup.+)
PRODUCTION EXAMPLE 30
2-Methyl-N,N'-dimethyl-N,N'-bis(3-hydroxyphenyl)-pyrimidine-4,6-diamine
(Exemplified Compound No. 1-31)
[0237] This compound was obtained (yield 45%) based on the method
described in Production Example 2B using
4,6-dichloro-2-methylpyrimidine instead of the
4,6-dichloro-2-ethylpyrimidine, and using 3-methylaminophenol
instead of the 3-aminophenol.
[0238] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 2.31(3H, s),
3.28(6H, s), 5.35(1H, s), 6.53-6.61(6H, m), 7.09(2H, t, J=8.0 Hz),
9.48(2H, brs).
[0239] Mass spectrum (EI), m/z: 336 (M.sup.+)
PRODUCTION EXAMPLE 31
6-Isobutyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-26)
[0240] This compound was obtained (yield 50%) based on the method
described in Production Example 1B using
6-isobutyl-2,4-dichloro-1,3,5-triazine instead of the
2,4-dichloro-6-ethyl-1,3,5-triazine.
[0241] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 0.99(6H, d,
J=6.8 Hz), 2.42(1H, m), 2.49(2H, d, J=7.2 Hz), 6.54(2H, dd, J=1.5,
8.0 Hz), 7.00-7.09(2H, m), 7.11(2H, t, J=8.0 Hz), 7.21(2H, m).
[0242] Mass spectrum (EI), m/z: 351 (M.sup.+)
PRODUCTION EXAMPLE 32
6-Ethyl-N,N'-bis(3-hydroxy-4-methylphenyl)-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-212)
[0243] This compound was obtained (yield 55%) based on the method
described in Production Example 1B using 3-amino-3-methylphenol
(sic) instead of the 3-aminophenol.
[0244] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 1.13(3H, t,
J=7.2 Hz), 1.96(6H, s), 2.51(2H, q, J=7.2 Hz), 6.87(2H, d, J=8.0
Hz), 6.98(2H, brs), 7.02(2H, d, J=8.0 Hz).
[0245] Mass spectrum (EI), m/z: 351 (M.sup.+)
PRODUCTION EXAMPLE 33
6-t-Butyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-36)
[0246] This compound was obtained (yield 48%) based on the method
described in Production Example 1B using
6-t-butyl-2,4-dichloro-1,3,5-triazine instead of the
2,4-dichloro-6-ethyl-1,3,5-triazine.
[0247] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 1.32(9H, s),
6.43(2H, dd, J=2.0, 8.0 Hz), 7.06(2H, t, J=8.0 Hz), 7.20(2H, brs),
7.34(2H, d, J=8.0 Hz), 9.27(2H, brs), 9.39(2H, brs).
[0248] Mass spectrum (EI), m/z: 351 (M.sup.+)
PRODUCTION EXAMPLE 34
6-s-Butyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine
(Exemplified Compound No. 4-31)
[0249] This compound was obtained (yield 52%) based on the method
described in Production Example 1B using
6-s-butyl-2,4-dichloro-1,3,5-triazine instead of the
2,4-dichloro-6-ethyl-1,3,5-triazine.
[0250] .sup.1H NMR spectrum (DMSO, 400 MHz), .delta.: 0.90(3H, t,
J=7.4 Hz), 1.26(3H, d, J=6.4 Hz), 1.59(1H, ddq, J=6.4, 7.4, 14.0
Hz), 1.83(1H, ddq, J=6.4, 7.4, 14.0 Hz), 2.60(1H, ddq, J=6.4, 6.4 ,
6.4 Hz), 4.00(2H, brs), 6.51(2H, d, J=7.2 Hz), 7.09(2H, d, J=7.5
Hz), 7.12(2H, s), 7.27(2H, d, J=7.5 Hz), 9.40(1H, brs), 9.90(1H,
brs).
[0251] Mass spectrum (EI), m/z: 351 (M.sup.+)
EXAMPLE 1
[0252] Action in Inhibiting the Lowering of MTT Reduction
Capacity
[0253] The HeLa cells employed were purchased from the Dainippon
Pharmaceutical Co.
[0254] The HeLa cells were seeded by suspension in MEM (Minimum
essential medium; produced by the Sigma Chemical Co.) containing
10% inactivated FBS (foetal bovine serum) such that there were
1,000 per well in a 96-well microplate, and then culturing was
carried out overnight in an incubator at 37.degree. C. in the
presence of 5% CO.sub.2.
[0255] The test compound was dissolved in dimethyl sulphoxide
(DMSO) and diluted with the MEM medium so that the final
concentration of DMSO was no more than 0.1 wt %, and added to the
cells seeded the previous day. A solution of .beta.-amyloid protein
(A.beta.1-40: produced by the Sigma Chemical Co.) dissolved in MEM
medium was added so the final A.beta.1-40 concentration was 100
ng/mL. Overnight culturing was carried out using an incubator at
37.degree. C. in the presence of 5% CO.sub.2, with 100 .mu.L/well
of MEM medium containing 5% deactivated FBS.
[0256] Now, prior to use, the. A.beta.1-40 had been dissolved in
buffer and left overnight so that the amyloid coagulated.
[0257] In order to determine the percentage inhibition of the test
compound, cells alone, cells where A.beta.1-40 had been added, and
cells where only the test compound had been added, were also
incubated overnight under the same conditions.
[0258] The following day, there was added 10 .mu.L/well of MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide:
produced by Wako Pure Chemical Industries] prepared at a
concentration of 5 mg/mL with phosphate buffered saline (PBS), and
incubation carried out for 2 hours at 37.degree. C. in the presence
of 5% CO.sub.2. The medium was then eliminated and the formazan dye
produced measured colorimetrically (A570 nm-A650 nm) using a
Microplate Reader (produced by the Molecular Devices Co.), by
dissolving with the addition of 100 .mu.L per well of isopropanol.
In this way, the change in the MTT reduction capacity of the HeLa
cells was measured.
[0259] The percentage inhibition (%) by the test compound was
determined from the following formula.
inhibition(%)[(a-b)/(a-c)].times.100
[0260] where [0261] a=MTT reduction capacity when untreated [0262]
b=MTT reduction capacity when A.beta.1-40 and the test compound are
added [0263] c=MTT reduction capacity when only A.beta.1-40 is
added
[0264] Table 6 shows the action in inhibiting the lowering of the
MTT reduction capacity by A.beta.1-40 (100 nM) in HeLa cells,
denoted by the 50% inhibitory concentration (IC50).
[0265] As can seen from Table 6, the compounds of the present
invention show outstanding action in inhibiting a lowering of the
MTT reduction capacity.
TABLE-US-00006 TABLE 6 Test Compound IC50 (.mu.m) compound of
Production Example 1 3.5 compound of Production Example 2 1.9
compound of Production Example 4 6.0 compound of Production Example
5 9.6 compound of Production Example 6 6.7 compound of Production
Example 8 5.5 compound of Production Example 9 2.4 compound of
Production Example 10 4.2 compound of Production Example 13 5.5
compound of Production Example 18 3.8 compound of Production
Example 27 2.4 compound of Production Example 33 2.2 compound of
Production Example 34 4.1 compound of Production Example 35 2.1
compound of Production Example 36 5.8
[0266] When testing was carried out by the same method as above
using 4-(7-hydroxy-2,4,4-trimethyl-chroman-4-yl)benzene-1,3-diol,
and the action in suppressing the lowering of MTT function measured
as the 50% inhibitory concentration (IC50), the measured result
obtained was 12 .mu.m.
EXAMPLE 2
[0267] Action in Suppressing Long-Term Potentiation Inhibition
[0268] The method for testing the suppression of the impairment of
long-term potentiation was based on that described in J. Neurosci.
Vol. 20, 2003-10 (2000). That is to say, acute.sup.i sections of
thickness 400 .mu.m were prepared from the hippocampus of the
brains of 3-4 week old male Wistar rats. These acute sections were
immersed in artificial cerebrospinal fluid in which .beta.-amyloid
protein (A.beta.1-42: produced by the Sigma Chemical Co.) and
compound from Production Examples 1 or 12 had been dissolved, and
pretreatment carried out for 5 hours.
[0269] In the measurement using the compound from Production
Example 1, the concentration of the A.beta.1-42 in the artificial
cerebrospinal fluid was 500 nM and the concentration of the
compound from Production Example 1 was 1 .mu.g/mL. In the
measurement using the compound from Production Example 12, the
concentration of the A.beta.1-42 in the artificial cerebrospinal
fluid was 1 .mu.m and the concentration of the compound from
Production Example 12 was 3 .mu.g/mL. Now, the A.beta.1-42 was used
after coagulation of the amyloid by leaving overnight.
[0270] 100 pulses of high frequency stimulation at 100 Hz were
applied to the pretreated acute sections, and the field excitatory
postsynaptic potential: fEPSP) measured by an extracellular
recording method.
[0271] The fEPSP was measured at 30 second intervals following
application of the high frequency stimulation and the fEPSP slope
(units [%]) measured. The average values of the slope over 0-20
minutes, 20-40 minutes and 40-60 minutes were determined. This test
was repeated five times over. The results are shown in Table 7. In
the table, the figures are the average values.+-.standard deviation
for the five averages obtained in the five tests. "Test 1" shows
the measurements employing the compound from Production Example 1
and "Test 2" shows the measurements employing the compound from
Production Example 12. "A.beta." denotes the A.beta.1-42.
[0272] As controls, measurements were made of the fEPSP [mV] under
the same conditions for acute sections pretreated with the
artificial cerebrospinal fluid alone, acute sections pretreated
with the artificial cerebrospinal fluid in which A.beta.1-42 had
been dissolved, and acute sections pretreated with artificial
cerebrospinal fluid in which only the compound from Production
Example 1 or 12 had been dissolved, and then the average value of
the fEPSP slope [%] obtained.
TABLE-US-00007 TABLE 7 Value of fEPSP Slope [%] 0-20 minutes 20-40
minutes 40-60 minutes Test 1 Control group 158.8 .+-. 5.2 157.5
.+-. 4.2 155.6 .+-. 5.4 A.beta. (500 nM) 145.8 .+-. 5.8 136.1 .+-.
4.0 113.0 .+-. 2.6 Prod. Ex. 1 compound* 155.3 .+-. 3.4 156.5 .+-.
3.9 155.8 .+-. 5.0 (1 .mu.g/mL) A.beta. (500 nM) + Prod. 150.0 .+-.
8.4 149.6 .+-. 6.9 151.2 .+-. 7.5 Ex. 1 compound (1 .mu.g/mL) Test
2 Control group 145.8 .+-. 5.8 136.1 .+-. 4.0 113.0 .+-. 2.6
A.beta. (1 .mu.M) 132.3 .+-. 8.8 114.4 .+-. 6.4 103.7 .+-. 5.4
Prod. Ex. 12 175.3 .+-. 7.4 162.9 .+-. 9.8 160.8 .+-. 10.3
compound** (3 .mu.g/mL) A.beta. (1 .mu.M) + Prod. 161.7 .+-. 2.6
148.1 .+-. 3.1 146.2 .+-. 4.6 Ex. 12 compound (3 .mu.g/mL) Notes:
*Prod. Ex. 1 compound = compound from Production Example 1 **Prod.
Ex. 12 compound = compound from Production Example 12
[0273] In the control group, by applying high frequency
stimulation, an increase in the synapse transmission was confirmed
over a 60 minute period. However, in the group where the sections
had been pretreated for 5 hours with A.beta.1-42, while long-term
potentiation was induced its maintenance was impaired.
[0274] In contrast, by pretreating for 5 hours with A.beta.1-42
together with the compound synthesized in Production Example 1 or
in Production Example 12, which is inactive on its own, the
impairment of the LTP due to the A.beta.1-42 was suppressed.
[0275] As can be seen in Table 7, the compounds of the present
invention show an outstanding suppression action against the
impairment of synapse transmission produced by A.beta..
[0276] Average values of the fEPSP slope [%] were determined in the
same way as in the test method described above, for
4-(7-hydroxy-2,4,4-trimethyl-chroman-4-yl)benzene-1,3-diol
(Compound A in the table). The measured values obtained are shown
below.
TABLE-US-00008 TABLE 8 Value of fEPSP Slope [%] 0-20 minutes 20-40
minutes 40-60 minutes Control group 158.7 .+-. 5.1 157.5 .+-. 4.1
155.5 .+-. 5.3 A.beta. (1 .mu.M) 133.5 .+-. 9.5 123.8 .+-. 6.6
122.8 .+-. 7.1 Compound A 168.6 .+-. 13.0 146.6 .+-. 15.9 149.7
.+-. 16.1 (1 .mu.g/mL) A.beta. (1 .mu.M) + 159.5 .+-. 6.6 142.8
.+-. 5.4 137.3 .+-. 4.5 Compound A (1 .mu.g/mL)
EXAMPLE 3
[0277] A.beta. Fibril-Formation Inhibiting Action and Fibrillar
A.beta. Breakdown Action
[0278] The A.beta. fibril-formation inhibiting action and fibrillar
A.beta. breakdown action were evaluated using the thioflavin
binding assay method. The details of the test method are based on
the method described in J. Biol. Chem. Vol. 274, 25945-25952
(1999).
[0279] In the measurement of the inhibition of A.beta.
fibril-formation, the concentration of the A.beta.1-42 was 25 .mu.M
and the concentration of the compound synthesized in Production
Example 4 or Production Example 12 was 100 .mu.g/mL in each case.
The measurement of the A.beta. fibril-formation inhibiting action
was carried out following incubation for 2 days at 37.degree. C. of
the A.beta.1-42 alone and of the A.beta.1-42 to which the compound
synthesized in Production Example 4 or Production Example 12 had
been added.
[0280] In the measurement of the fibrillar A.beta. breakdown
action, the concentration of the A.beta.1-42 was 25 .mu.M and the
concentration of the compound synthesized in Production Example 4
or Production Example 12 was 100 .mu.g/mL in each case. After
incubating the A.beta.1-42 for 2 days or 3 days at 37.degree. C.,
the compound synthesized in Production Example or Production
Example 12 was or was not added, and then further incubation
performed for 2 days, after which measurement of the fibrillar
A.beta. breakdown action was performed.
[0281] The measurements of the A.beta. fibril-formation inhibiting
action and of the fibrillar A.beta. breakdown action were carried
out by placing a 100 .mu.L sample obtained by pretreatment as
described above, plus 800 .mu.L of distilled water, 1 mL of glycine
(100 mM) and 50 .mu.L of thioflavin (100 .mu.M) in a cuvette, and
measuring the fluorescence at an excitation wavelength of 435 nm
and a fluorescence wavelength of 490 nm.
[0282] The results are shown in Table 9. The figures in the table
show the calculated percentages taking the fluorescent intensity
obtained when the fluorescence of the sample obtained by incubating
A.beta.1-42 (25 .mu.M) alone by the above method, and measured at
an excitation wavelength of 435 nm and a fluorescence wavelength of
490 nm, was taken as 100. The figures are in the form of the
average value.+-.standard deviation, for the three to nine averages
obtained in three to nine tests. In the table, "Test 3" shows the
measurements using the compound from Production Example 4, and
"Test 4" shows the measurements using the compound from Production
Example 12. "A.beta." is for the A.beta.1-42.
TABLE-US-00009 TABLE 9 fibril-formation fibrillar inhibiting action
breakdown action (fluorescent (fluorescent intensity %) intensity
%) Test 3 A.beta. (25 .mu.M) 100.00 .+-. 1.18 100.00 .+-. 8.88
A.beta. (25 .mu.M) + Prod. Ex. 4 16.26 .+-. 5.30 30.63 .+-. 1.26
compound* (100 .mu.g/mL) Test 4 A.beta. (25 .mu.M) 100.00 .+-. 2.24
100.00 .+-. 2.07 A.beta. (25 .mu.M) + Prod. Ex. 12 1.69 .+-. 1.324
28.49 .+-. 5.17 compound** (100 .mu.g/mL) Notes: *Prod. Ex. 4
compound = compound from Production Example 4 **Prod. Ex. 12
compound = compound from Production Example 12
[0283] With A.beta. by itself, strong thioflavin fluorescence was
confirmed. This shows that A.beta. forms fibrils. However, in the
samples obtained by adding the compound from Production Example 4
or from Production Example 12 prior to fibril formation, there was
a weakening of the thioflavin fluorescence, indicating that the
A.beta. fibril-formation was inhibited. The same results were also
obtained with samples obtained by adding the compound from
Production Example 4 or Production Example 12 after fibril
formation, indicating that there was a fibrillar A.beta. breakdown
action.
[0284] As shown in Table 8 (sic), as well as the compounds of the
present invention acting to inhibit A.beta. fibril-formation, it is
clear that they also act to break down formed A.beta. fibrils.
PREPARATION EXAMPLE 1
A Powder Preparation Comprising the Compound from Production
Example 1
[0285] When 5 g of the compound from Production Example 1, 895 g of
lactose and 100 g of corn starch are mixed together, a powder
preparation is obtained.
PREPARATION EXAMPLE 2
Granules Comprising the Compound from Production Example 1
[0286] After mixing 5 g of the compound from Production Example 1,
865 g of lactose and 100 g of hydroxypropyl cellulose of low degree
of substitution, 300 g of 10% aqueous hydroxypropyl cellulose
solution is added and kneading performed. The mixture is extruded
and granulated using a granulator, and then dried to obtain a
granular preparation (granules).
PREPARATION EXAMPLE 3
Capsules of the Compound of Production Example 1
[0287] After mixing together 5 g of the compound from Production
Example 1, 115 g of lactose, 58 g of corn starch and 2 g of
magnesium stearate using a V-shape mixer, No. 3 capsule containers
are filled with 180 mg quantities of the mixture and capsules
obtained.
PREPARATION EXAMPLE 4
Tablets of the Compound of Production Example 1
[0288] After mixing together 5 g of the compound from Production
Example 1, 90 g of lactose, 34 g of corn starch, 20 g of
crystalline cellulose and 1 g of magnesium stearate in a blender,
tableting is carried out with a tableting machine and tablets
obtained.
INDUSTRIAL APPLICATION POTENTIAL
[0289] The drugs of the present invention which contain a compound
of general formula (I) are outstanding in their action in
suppressing the fall in MTT reduction capacity brought about by
.beta.-amyloid protein, and in inhibiting impairment of long-term
potentiation of hippocampal nerve cells, so they are useful as
preventatives or remedies for Alzheimer's disease.
[0290] The amyloid protein fibril-formation inhibitors of the
present invention are outstanding in their action in inhibiting
amyloid protein fibril-formation and in their fibrillar amyloid
protein breakdown action, so they are valuable as preventatives or
remedies for amyloidosis, such as Alzheimer's disease, type 2
diabetes, immunoglobulinic amyloidosis, reactive amyloidosis,
familial amyloidosis, dialysis-related amyloidosis, senile
amyloidosis, cerebrovascular amyloidosis, hereditary cerebral
haemorrhage with amyloidosis, Creutzfeldt-Jakob disease, bovine
spongiform encephalitis (BSE), scrapie, medullary carcinoma of the
thyroid, insulinoma, localized atrial amyloid, amyloidosis cutis
and localized nodular amyloidosis, preferably for Alzheimer's
disease, type 2 diabetes, dialysis-related amyloidosis, familial
amyloidosis, Creutzfeldt-Jakob disease and BSE, in particular for
Alzheimer's disease and type 2 diabetes.
[0291] Furthermore, the nitrogen-containing heteroaryl derivatives
of the present invention and their pharmacologically permitted
salts are valuable as preventives or remedies for Alzheimer's
disease of warm-blooded animals (in particular humans), or as
amyloid protein fibril-formation inhibitors.
* * * * *